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Abstract 
Observational studies have suggested an association between low levels of niacin and 
vitamin D and increased cardiovascular disease risk. Both vitamins have been shown to 
improve endothelial functions and vascular regeneration following vascular injury, however, 
it appears vitamin D may promote or inhibit neovascularization in a context-dependent 
manner. We hypothesized that supplementation of vitamin D alone and in combination with 
niacin, would improve endothelial cell function under lipotoxic conditions and promote 
revascularization and functional recovery in obese mice with ischemic injury. Matrigel 
assays, mRNA microarray analyses and growth rate assays were used to investigate 
angiogenic function of endothelial cells exposed to the saturated fatty acid, palmitate. 
Supplementation with vitamin D, niacin, and the combination improved endothelial tube 
formation and stability in high palmitate. Supplementation with vitamin D markedly 
decreased expression of cell cycle regulators, where niacin induced stable expression of 
miR126, a known regulator of angiogenesis. In diet-induced obese mice with acute ischemic 
injury, treatment with niacin, but not vitamin D or the combination, improved hind limb 
functional recovery. No significant improvements in revascularization, regeneration, 
inflammation, or fibrosis were observed. In conclusion, although both vitamins promoted in 
vitro endothelial cell angiogenic function, only niacin improved functional recovery 
following ischemic injury.  
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Summary for Lay Audience 
In Canada, obesity, diabetes and metabolic syndrome are on the rise, especially among 
Canada’s Indigenous population. These diseases often lead to damaged blood vessels and 
cardiovascular diseases such as heart attack, stroke, hypertension, atherosclerosis and loss of 
blood flow to the lower legs, which can lead to amputation. These complications occur 
during obesity and diabetes due to the high levels of fats and sugars in the blood stream that 
damage endothelial cells, which make up the inner lining of blood vessels and maintain 
vessel function. One of the biggest challenges to our health care system is finding effective 
treatment options for patients with vascular disease. Both niacin (vitamin B3) and vitamin D 
have potential as alternative or complementary treatment options for vascular disease as they 
have been show to improve and maintain the function of endothelial cells. This project 
investigated whether vitamin D alone or in combination with niacin, could improve the 
ability of blood vessels to repair and regrow following damage caused by high fats. 
Supplementation with vitamin D, niacin, and the combination improved the ability of 
endothelial cells to form blood vessels in an experimental dish. However, in obese mice with 
hind leg blood vessel injury, supplementation with niacin alone, but not vitamin D or the 
combination, improved functional recovery of the hind leg. It is possible that vitamin D may 
limit the growth of new blood vessels during obesity as it was also found that vitamin D 
decreased the growth and expansion of endothelial cells when exposed to high fat. These 
findings raise questions as to effectiveness of vitamin D supplementation to promote 
cardiovascular health in a high fat setting such as obesity or metabolic syndrome. Ultimately, 
better understanding of the effects of nutritional compounds on blood vessels will help guide 
therapeutic and dietary recommendations for the promotion of vascular health. 
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1 Introduction 
1.1 Obesity, Metabolic Syndrome and Ischemic Peripheral 
Vascular Disease 
Worldwide prevalence of obesity has nearly tripled since 1975, with its prevalence only 
expected to increase in years to come. As of 2016, the World Health Organization 
estimated that more than 650 million people worldwide are obese (World Health 
Organization, 2016). More shockingly, the prevalence of obesity among children and 
adolescents has risen from 4% to 18% in the span of 41 years (World Health 
Organization, 2016). Historically, obesity has been regarded as a high-income country 
problem, with the highest prevalence observed in the Americas; however it is currently 
on the rise in low- and middle-income countries (World Health Organization, 2016). 
Increased prevalence of obesity is largely attributed to the increased consumption of 
calorie dense, highly palatable foods that are high in fat and sugar (Crino et al., 2015).  
Increased calorie consumption, coupled with decreased physical activity due to an 
increasingly sedentary lifestyle further drive this increased prevalence of obesity in the 
western world (Unger & Scherer, 2010; Sturm & An, 2014). 
The World Health Organization defines obesity as having abnormal or excess 
accumulation of adipose tissue that may be detrimental to health (World health 
organization, 2016). In order to be classified as obese, a body mass index (BMI = weight 
[kg] / height
2 
[m
2
]) of >30 kg/m
2
 is required. Although BMI has been used clinically for 
centuries to classify obesity, its use has been scrutinized and found to be an ineffective 
tool to measure associations between weight and cardiometabolic health. Rather, medical 
practitioners should consider ectopic adipose tissue distribution within the body as an 
indicator of weight and cardiometabolic health (Tomiyama et al., 2016). Specifically, 
abdominal obesity, or excess fat accumulation around the waist or abdomen, is a key risk 
factor for the development of metabolic syndrome and other chronic diseases such as 
type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD) (Mokdad et al., 2003; 
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Després & Lemieux, 2006). The most common and prevalent downstream complication 
associated with abdominal obesity is metabolic syndrome. Due to the many physiological 
and metabolic disturbances that occur during metabolic syndrome, there is an increased 
risk for the development of other co-morbidities such as CVD, T2DM and all-cause 
mortality (O’Neill & O’Driscoll, 2015). Metabolic syndrome is diagnosed when a patient 
presents with at least 3 of the following 5 criteria: elevated blood pressure >130/85 
mmHG, elevated fasting blood glucose level >5.6 mmol/L, high triglycerides (TG) >1.7 
mmol/L, low levels of high density lipoprotein (HDL) <1.0 mmol/L in men or <1.3 
mmol/L in women or an increased waist circumference >102 cm in men or >88 cm in 
women (Metabolic Syndrome Canada, 2019).  
Under normal physiological conditions, adipocytes are able to compensate for caloric 
excess and inactivity by expanding their lipid depots  (adipose hypertrophy)  and through 
adipogenesis (adipose hyperplasia) to maximize storage of diet-derived plasma lipids in 
the form of TG (Virtue & Vidal-Puig, 2010). During periods of fasting, stored TG can 
undergo lipolysis to provide energy to other organs, in the form of free fatty acids (Unger 
& Scherer, 2010). Adipocytes are both an endocrine and paracrine organ and secrete 
various factors, or adipokines, that can influence different metabolic and vascular 
processes. In the setting of obesity, concomitant with adipocyte hypertrophy, is a 
proportional increase in leptin secretion from adipocytes that targets the hypothalamus to 
reduce food consumption (Unger & Scherer, 2010; Harman S. Mattu, 2013). Leptin also 
has a physiological role, via leptin-induced fatty acid oxidation, to minimize the 
accumulation of lipids in cell types other than adipocytes (Unger & Scherer, 2010). 
Hyperleptinaemia may contribute to the pathophysiology of metabolic syndrome and 
CVD during obesity, as it is associated with insulin resistance, platelet aggregation and 
arterial thrombosis (Van Gaal et al., 2006). Adipocytes can further contribute to the 
pathophysiology of obesity and metabolic syndrome through the secretion of 
proinflammatory molecules such as tumour necrosis factor alpha (TNFα), interleukin-6 
(IL-6), and monocyte chemoattractant protein-1 (MCP-1), leading to a sustained pro-
inflammatory state (Van Gaal et al., 2006; Campia et al., 2012), which has been shown to 
induce insulin resistance and increase the risk for the development of metabolic 
syndrome (Odegaard & Chawla, 2013).  
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Under sustained conditions of increased caloric intake and decreased physical activity, 
the ability of adipocytes to store excess lipids is exceeded,  resulting in uncontrolled TG 
lipolysis and subsequent increase in circulating fatty acids (van Herpen & Schrauwen-
Hinderling, 2008). Adipose hypertrophy, rather than adipose hyperplasia, is associated 
with impaired adipocyte function, inflammation, insulin resistance, metabolic disease and 
cardiovascular risk (Skurk et al., 2007; Sun et al., 2011). An increased flux of fatty acids 
from  dysfunctional adipocytes can partially account for hypertriglyceridemia seen in 
patients with metabolic syndrome, as the liver generates more very low density 
lipoproteins (VLDL) in response to increased substrate availability (van Herpen & 
Schrauwen-Hinderling, 2008). Increased plasma levels of fatty acids and lipoproteins 
during chronic hyperlipidemia, can lead to steatosis, or the abnormal accumulation of 
fatty acids in tissues, such as the liver, heart, skeletal muscle, and vasculature, that are not 
metabolically programmed to store these excess lipids (van Herpen & Schrauwen-
Hinderling, 2008). Steatosis can disruption cellular signaling and tissue homeostasis, 
leading to cell death in various tissues and organs, through a process termed lipotoxicity 
(Wende et al., 2012; Dalan et al., 2014). 
Cardiovascular diseases are some of the most prevalent downstream complications 
associated with obesity and metabolic syndrome (Campia et al., 2012; Brostow et al., 
2012). Vascular complications arise in multiple tissue sites and vascular beds in response 
to excess circulating fatty acids. In addition to fatty acid accumulation within vascular 
endothelium, the inflammatory response induced by vascular steatosis results in 
macrophage recruitment and subsequent plaque formation in large and medium sized 
arteries (Talayero & Sacks, 2011). Plaque development occludes arteries contributing to 
the hypertensive state observed during metabolic syndrome. Over time, plaques may 
become unstable and are at risk of rupture that can lead to myocardial infarction and 
stroke (Libby, 2012; Manduteanu & Simionescu, 2012). Beyond large and medium sized 
arteries, plaques may also develop in peripheral vascular beds, disrupting blood flow to 
the extremities, and lead to the development of peripheral vascular disease (PVD) 
(Brostow et al., 2012; Teodorescu et al., 2013). Left untreated, patients can develop end 
stage PVD, or critical limb ischemia, and may require limb amputation (Teodorescu et 
al., 2013).  Metabolic syndrome is associated with increased incidence of CVD 
4 
 
 
morbidity, mortality and all-cause mortality (Galassi et al., 2006), as well as increased 
incidence of CVD endpoints, including ischemic stroke (Chen et al., 2006), PVD (Garg 
et al., 2014) and end stage PVD (Gardner et al., 2006). Therefore, prevention and 
intervention strategies protecting against vascular damage during obesity and metabolic 
syndrome are warranted.   
1.2 Endothelial Cell Damage during Obesity and Metabolic 
Syndrome  
Vascular endothelial cells (EC) serve many physiological functions, playing a critical role 
in the maintenance of vascular homeostasis.  The endothelium lines the entire circulatory 
system acting as a physical barrier between the lumen and vessel wall. EC have both a 
sensory and effector capacity to regulate thrombosis, platelet and leukocyte activity, 
vascular permeability, fibrinolysis and immune modulation (Bonetti et al., 2003). In 
addition, EC secrete a number of mediators that regulate vascular tone, such as 
endothelin-1 (ET-1) and thromboxane A2 (TXA2) for vasoconstriction, and nitric oxide 
(NO) for vasodilation (Rajendran et al., 2013). Furthermore, EC play a critical role in the 
maintenance of vascular structure through angiogenesis and are responsible for vascular 
regeneration and repair following injury (Imrie et al., 2010). Therefore, disruption of EC 
function can play a critical role in the pathogenesis of many vascular diseases common to 
obesity and metabolic syndrome.  
Endothelial dysfunction, in a broad sense, is characterized by a shift in EC physiology 
that results in an imbalance of vascular tone regulators leading to disrupted vascular 
homeostasis (Endemann & Schiffrin, 2004). More specifically, there is an observed 
decrease in the important vasodilator, NO, with a corresponding increase in 
vasoconstrictor factors (Campia et al., 2012; Symons & Abel, 2013). It is also understood 
that beyond the imbalance in vasoregulators, EC dysfunction comprises EC activation 
that induces a pro-inflammatory, proliferative and pro-coagulator state. Endothelial 
dysfunction is associated with obesity and metabolic syndrome (Steinberg et al., 1996) 
and has been identified as a surrogate marker for vascular disease onset and progression, 
including the common and often underdiagnosed, condition of PVD (Vita & Hamburg, 
2010; Campia et al., 2012). More interestingly, endothelial dysfunction has been shown 
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to precede overt symptoms of metabolic syndrome and obesity, suggesting that it may 
contribute to the development of both the vascular and metabolic disturbances associated 
with these diseases (Campia et al., 2012; Grandl & Wolfrum, 2018). 
Initially, EC respond and adapt to vascular stress and changes in their microenvironment 
by modulating their constitutive functions. However, under continued or prolonged 
insults, such as hyperlipidemia, hyperglycemia or hemodynamic stress, endothelial 
dysfunction arises, leading to EC injury and eventual apoptosis (Simionescu, 2007; Kim 
et al., 2012). An early adaptation of EC function in response to hyperlipidemia during 
obesity and metabolic syndrome involves altered EC permeability, such that LDL and 
VLDL can accumulate in the subendothelium (Simionescu, 2007). This shift in 
permeability is accompanied by alteration in EC secretory phenotype, where EC 
synthesize surface adhesion molecules, such as selectins, including vascular cell adhesion 
molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1), chemotactic 
factors, particularly MCP-1 and IL-8, and vasoactive substances (Simionescu, 2007). 
Expression of these molecules facilitates leukocyte-endothelial interactions, promoting 
monocyte recruitment and generation of a chronic inflammatory state (Grover-Páez & 
Zavalza-Gómez, 2009; Rajendran et al., 2013). Endothelial NO has been identified as an 
important molecule for maintenance of vascular function under normal physiological 
conditions. Insults to EC can reduce or even abolish NO function. Reduced NO 
bioavailability further contributes to the upregulation of VCAM-1 in EC via the nuclear 
factor κB (NF-κB) pathway augmenting the inflammatory response (Kuldo et al., 2005).  
Pathogenesis of endothelial dysfunction and progression of vascular disease is largely 
dependent on vessel type and location within the human body. Presentation of endothelial 
dysfunction in large arteries represents a crucial role in the early development of lipid-
rich foam cell formation, lesion evolution and eventual atherosclerotic plaques formation. 
Conversely, at the level of microvessels, endothelial dysfunction results in disruption of 
blood flow and vasoreactivity (Abularrage et al., 2005; Avogaro & de Kreutzenberg, 
2005). Microvascular endothelial dysfunction is more closely related to development and 
progression of PVD rather than atherosclerosis. Furthermore, microvascular endothelial 
dysfunction precedes atherosclerotic plaque formation making it an important early 
marker of vascular disease during obesity and metabolic syndrome (Verma et al., 2003). 
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Therefore, prevention and intervention strategies for PVD should target endothelial 
dysfunction. However, currently available pharmacotherapies for PVD are limited and 
generally focus on symptom relief for thrombosis and claudication pain management 
rather than promoting endogenous revascularization of the ischemic tissues (Farber & 
Eberhardt, 2016). Patients who develop end stage PVD, have the option to undergo 
surgical revascularization to increase chances of limb salvage, but this method is rather 
invasive and further highlights the need for more therapeutic treatments targeting the 
promotion of endothelial function and endogenous vascular regeneration (Saghiri et al., 
2017). 
1.3 Endothelial Cell Lipotoxicity  
High levels of circulating fatty acids are key endothelial stressors during metabolic 
diseases. Lipotoxicity is the process by which lipid accumulation results in alteration of 
tissue homeostasis that leads to cell dysfunction and eventual apoptosis (Imrie et al., 
2010; Kim et al., 2012).  EC are especially vulnerable to lipotoxicity as they form the 
inner most layer of the vasculature and are constantly exposed to high levels of 
circulating lipids (Wende et al., 2012). Furthermore, EC’s main energy source is derived 
from aerobic glycolytic ATP, and therefore EC lack the metabolic programing to 
efficiently process excess lipids through β-oxidation.  Due to the inability of EC to 
processes large quantities of lipids, metabolic stress pathways are activated and resulting 
in the generation of reactive oxygen species (ROS) that contribute to endothelial 
dysfunction (Wende et al., 2012). Figure 1.1 provides a summary of EC lipotoxicity and 
related pathways during obesity and metabolic syndrome, which are discussed in detail 
below.  
Fatty acids are classified as either saturated or unsaturated fatty acids. It is largely 
recognized that saturated fatty acids are responsible for CVD, where unsaturated fatty 
acids are well tolerated by cells and may actually protect against CVD (Ghosh et al., 
2017). Experimental work in EC has demonstrated that saturated fatty acids, such as 
palmitate, induce cellular apoptosis in a dose-dependent manner, where unsaturated fatty 
acids do not (Staiger et al., 2006; Ciapaite et al., 2007). Palmitate is one of the most  
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Figure 1.1 Summary of endothelial dysfunction and related pathways during obesity 
and metabolic syndrome. 
During obesity and metabolic syndrome (1) there is accumulation of lipids in adipocytes 
(2). Once adipocyte capacity is exceeded uncontrolled, dysregulated lipolysis occurs (3), 
releasing excess fatty acids into circulation (4). Endothelial cells are continuously 
exposed to high levels of circulating lipids as they comprise the inner most layer of 
vasculature. Endothelial cells lack the metabolic programming to process excess fatty 
acids. Excess palmitate, an abundant dietary saturated fatty acid, can overwhelm the 
ability of a cell to store fatty acids in lipid droplets or to catabolize them through β-
oxidation in mitochondria. This can result in production of reactive oxygen species 
(ROS) and ER stress, resulting in endothelial dysfunction and eventual death, through a 
process termed lipotoxicity. Palmitate can also readily be incorporated into the ER lipid 
membrane, resulting in impaired membrane structure and integrity. Oxidative stress and 
ER stress result in release of calcium from the ER further contributing to mitochondrial-
mediated cell death (5). 
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abundant saturated fatty acids occurring in a typical western-diet, and has been identified 
as a strong contributing factor to atherosclerosis development (Yamagishi et al., 2002; Lu 
et al., 2013). Several studies have shown that animals fed a western style diet high in 
saturated fats resulted in various metabolic and vascular disturbances, including 
atherosclerosis and PVD (Breslow, 1996; Coenen et al., 2009; Wang et al., 2009). 
During exposure to excess fatty acids, especially saturated fatty acids, toxic bioactive 
lipid metabolites can accumulate, contributing to impaired metabolic homeostasis and 
endothelial dysfunction. Ceramides are precursors for sphingolipids in cells, both of 
which have been recognized as initiators of cell stress response and eventual apoptosis 
following cellular injury (Chaurasia & Summers, 2015). Inhibition of ceramide 
biosynthesis has been demonstrated to prevent various cardiovascular events, including 
endothelial dysfunction. Ceramides are produced in response to saturated fatty acid 
metabolism and have been shown to decrease eNOS activity and contribute to endothelial 
dysfunction (Xiao-yun et al., 2009). Using aortic EC, Zhang et al. (2012) showed that 
increased de novo ceramide production was associated with reduced eNOS activation and 
NO bioavailability by initiating colocalization of eNOS with protein phosphatase 2A 
(PP2A) and preventing Akt-associated activation. Furthermore, treatment of EC with 
ceramide elicited signalling events that led to increased ROS generation (Zhang et al., 
2012b), which has been show to occur upstream of eNOS inhibition and mediated in an 
NADPH dependent manner (Mugabo et al., 2011).  Ceramide production has also been 
associated with impaired EC functions such as decreased cell proliferation and migration 
(Bocci et al., 2012). Ceramide accumulation in response to excess palmitate outlines one 
mechanism by which lipotoxicity contributes to endothelial dysfunction and eventual cell 
death. 
Saturated fatty acids, such as palmitate, have been shown to readily induce EC 
inflammatory pathway activation that has been shown to contribute to endothelial 
dysfunction (Kim et al., 2005; Liu et al., 2012). Several studies have reported increased 
activation of the NF-κB inflammatory pathway in response to fatty acids, resulting in 
decreased NO production and a dysfunctional phenotype (Staiger et al., 2006; Iwata et 
al., 2011; Li et al., 2011). Kim et al. (2007) demonstrated that palmitate signals via toll-
like receptor-4 (TLR4) in EC to upregulate the expression of inflammatory genes, such as 
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IL-6 and TNFα. Increased expression of these inflammatory genes is associated with 
impaired insulin signalling and reduced NO production in vascular EC (Kim et al., 2007). 
Follow-up studies from this group have demonstrated that palmitate-induced TLR4 
activation was associated with NADPH-dependent ROS production in human 
microvascular endothelial cells (HMVEC), which was required for the inflammatory 
response elicited by palmitate (Maloney et al., 2009). Fatty acids have also been shown 
to induce the expression of inflammasomes, which are large cytoplasmic complexes from 
the NOD-like receptors family of pattern-recognition receptors (Abderrazak et al., 2015). 
Inflammasomes are responsible for the activation of caspases, which leads to the 
activation of pro-inflammatory cytokines, such as IL-1β and IL-18 (Martinon et al., 
2002). NLRP3 is the most versatile and clinically relevant inflammasome as several 
inflammatory diseases such as obesity, atherosclerosis and T2DM have been linked to 
NLRP3 activation (Leemans et al., 2011). A recent study by Wang et al. (2016) 
demonstrated that treatment of microvascular EC with palmitate activated NLRP3, which 
was associated with decreased expression of endothelial tight junction proteins and the 
promotion of a dysfunctional EC phenotype.  
Oxidative stress and increased ROS production have been identified as a key player in the 
development EC dysfunction during lipotoxicity. Mitochondria are a major source of 
ROS and oxidative stress. Exposure to palmitate has been show to increased ROS 
production in skeletal muscle cells (Jheng et al., 2012) and in vascular EC (Szewczyk et 
al., 2015; Broniarek et al., 2016) due to incomplete mitochondrial β-oxidation. Another 
major source of ROS production in EC that has grown much attention is NADPH 
oxidase. More specifically, treatment of EC with palmitate has been shown to increase 
ROS production in an NADPH-oxidase dependent manner, which was associated with 
endothelial dysfunction in obese, diabetic rats (Chinen et al., 2007). Production of ROS 
in EC can impair NO bioavailability via disrupted oxidant/antioxidant balance. Excess 
ROS has been shown to react with NO to form peryoxynitrite and lead to a disruption in 
eNOS activity and decreased NO bioavailability (Zou et al., 2002; Molnar et al., 2005; 
Fonseca et al., 2010). Furthermore, various pathways contributing to ROS production can 
synergistically interact to generate an increasingly dysfunctional phenotype. For example, 
NADPH-oxidase-derived ROS can enhance mitochondrial ROS production resulting in a 
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vicious cycle of increased ROS production, reduced NO bioavailability and increased 
endothelial dysfunction (Imrie et al., 2010; Zorov et al., 2014). 
Excess saturated fatty acids have also been shown to induce endoplasmic reticulum (ER) 
stress outlining another mechanism of fatty acid induced endothelial dysfunction (Li et 
al., 2015). Several studies have shown that endothelial ER stress leads to increased 
NADPH-oxidase expression, decreased eNOS activity and increased ROS production 
(Santos et al., 2014; Galán et al., 2014; Li et al., 2015). Palmitate has been shown to 
inhibit EC proliferation, increase ROS production and induce endothelial apoptosis via 
upregulation of the ER stress marker, C/EBP homologous protein (CHOP) (Lu et al., 
2013). A recent study by Tampakakis et al. (2016) demonstrated that elevated fatty acids 
following intralipid infusion in healthy patients, induced characteristics of microvascular 
dysfunction along with activation of activating transcription factor 6 (ATF6) and inositol-
requiring enzyme 1 (IRE1) in EC, both of which are early markers of ER stress response.  
Lastly, excess fatty acids can induce ER stress through disruption of ER membrane. 
Palmitate has been shown to be rapidly incorporated into ER membrane phospholipids 
disrupting membrane integrity and initiate apoptosis (Borradaile et al., 2006).  
1.4 Niacin and the Regulation of Lipid Metabolism and 
Vascular Function 
Niacin (vitamin B3) has been used in the clinical setting for decades to correct high lipid 
profiles, particularly hypertriglyceridemia, in patients at risk for CVD (Digby et al., 
2012b).  Pharmacological doses of niacin have been shown to provide clinical benefit in 
the setting of metabolic disease by lowering the pro-atherogenic lipid species, VLDL and 
LDL, while simultaneously increasing the anti-atherogenic high-density lipoprotein 
(HDL) fractions, resulting in improved lipid profiles (Thoenes et al., 2007; Creider et al., 
2012). Despite the clinical benefit of niacin, its use has been hindered by a lack of patient 
compliance due to its adverse, yet relatively harmless, cutaneous flushing experienced 
with niacin supplementation. 
Niacin has been shown to elicit some effects through the cell surface receptor, GPR109A. 
This is a seven-transmembrane G-protein coupled receptor that has a high affinity for 
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niacin and was first identified in 2003 (Tunaru et al., 2003; Wise et al., 2003; Soga et al., 
2003). GPR109A is widely expressed in different cell types including immune cells 
(Yousefi et al., 2000; Schaub et al., 2001), intestinal epithelium (Thangaraju et al., 2009), 
and epidermal Langerhans cells (Maciejewski-Lenoir et al., 2006). Activation of 
GPR109A in Langerhans cells, and subsequent production of the vasodilatory compound 
prostaglandin D2 (PGD2), is responsible for the cutaneous flushing experienced with 
niacin treatment. The most robust expression of GPR109A is found on both brown and 
white adipocytes and accounts for the anti-lipolytic effects of niacin (Tunaru et al., 2003). 
More importantly, research from our lab confirmed GPR109A expression in vascular EC 
(Hughes-Large et al., 2014).  
As early as 1960s, the effect of niacin on lipid profiles has largely been attributed to the 
partial inhibition of adipocyte lipolysis. Niacin has been shown to activate GPR109A in 
adipocytes to inhibit adenylyl cyclase, reduce cyclic monophosphate (cAMP) 
accumulation and decrease adipocyte TG hydrolysis and fatty acid release (Lukasova et 
al., 2011; Yadav et al., 2012). The resultant decrease in fatty acid efflux limits substrate 
availability for hepatic TG synthesis and assembly of VLDL and LDL (Zhang et al., 
2005; Offermanns, 2006). However, more recent findings have found that niacin causes a 
robust rebound in adipocyte lipolysis that actually results in increased plasma fatty acid 
levels over 24 h following treatment (Oh et al., 2011). Moreover, in mice lacking 
GPR109A, niacin treatment failed to produce an anti-lipolytic effect, but retained its lipid 
lowering effect (Lauring et al., 2012).  Thus it has been suggested that inhibition of 
adipose lipolysis is unlikely to be the limiting factor for hepatic TG synthesis (Kamanna 
& Kashyap, 2008).  
Independent of GPR109A, niacin can directly target the liver to exert its effects on lipid 
profiles. Diacylglycerol acyltransferase 2 (DGAT2) is a key enzyme involved in the final 
catalysis step of hepatic TG synthesis. Niacin has been shown to directly and 
noncompetitively inhibit microsomal DGAT2 in HepG2 cells (Ganji et al., 2004; 
Kamanna et al., 2013). Due to decreases in hepatic TG synthesis there were observed 
increases in apolipoprotein B (ApoB) degradation, with a resulting decrease in hepatic 
secretion of VLDL and LDL. In support of this concept, findings from a small human 
study reported reduced hepatic lipid content following 23 weeks of treatment with 
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extended release niacin (2 g/day). Their results suggested that the mechanism may be due 
to inhibition of DGAT2, as DGAT2 polymorphisms were associated with smaller 
reduction in hepatic lipid content (Hu et al., 2012). Furthermore, rats fed a high-fat diet 
had decreased hepatic lipid content and displayed significant inhibition of mRNA levels, 
protein expression, and activity of DGAT2 following treatment with niacin (Ganji et al., 
2014). Results obtained in mice suggest that niacin may also inhibit hepatic peroxisome 
proliferator-activated receptor gamma coactivator 1-β (PGC-1β) expression resulting in 
decreased ApoC3 and reduced TG synthesis (Hernandez et al., 2010).   
Niacin has long been recognized for its ability to raise HDL levels; however mechanisms 
behind this effect remain complex and rather elusive (Pang et al., 2014).  Kamanna et al. 
(2013) have proposed that niacin may reduce hepatic removal of HDL from circulation 
via down regulation of β-ATP synthase expression. Niacin may also enhance HDL 
formation by increasing lipidation of ApoA1 with cholesterol (Zhang et al., 2012a). 
Further studies have revealed this effect may be a result of enhanced lipid efflux from 
peripheral tissues via transcription of hepatic ABCA1 (Kamanna et al., 2013). Although 
niacin’s involvement in augmenting HDL are complex and not well understood, niacin 
has been shown to improve the protective function of HDL on EC to limit the progression 
of atherosclerosis (Sorrentino et al., 2010; Ganji et al., 2014). Niacin’s protective role 
may be associated with macrophage-mediated reverse cholesterol transport (Rubic et al., 
2004; Lukasova et al., 2011). Niacin, through activation of GPR109A on macrophages 
can increase cholesterol efflux onto HDL particles via the ABCG1 transporter to reduce 
atherosclerosis progression (Lukasova et al., 2011). Specific to EC, in patients with 
T2DM, treatment with extended release niacin showed improved HDL capacity to 
stimulate NO production, endothelial repair and decrease oxidative stress (Sorrentino et 
al., 2010). More recent evidence has demonstrated that niacin may preserve HDL 
function by limiting HDL oxidation. Ganji et al. (2014) have shown that niacin decreased 
NADPH oxidase and ROS production, which was associated with reduced leukocyte 
myeloperoxidase (MPO) activity and decreased HDL oxidation.  
Results from the large clinical trials HPS2-THRIVE (Haynes et al., 2013) and AIM-
HIGH (Albers et al., 2013) have brought in to question the use of niacin for 
cardiovascular benefit in the treatment of dyslipidemia. These trials were designed to 
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assess whether the addition of niacin to statin therapy offered any additional 
cardiovascular benefit. Both trials were stopped due to a lack of additional cardiovascular 
benefit. However, many criticisms of both trials have been published and suggest either 
study may have been insufficient to identify the cardiovascular benefits of niacin (Digby 
et al., 2012b; Michos et al., 2012; Song & FitzGerald, 2013; Superko et al., 2017)  
Despite the disappointing results from AIM-HIGH and HPS2-THRIVE, niacin 
intervention has consistently been shown to improve vascular health in several patient 
populations  (Creider et al., 2012), including those with metabolic disturbances (Thoenes 
et al., 2007; Guyton et al., 2013; Toth et al., 2015). As outlined in section 1.3, vascular 
inflammation and oxidative stress have been identified as important contributors to 
endothelial dysfunction during lipotoxicity, and reductions in these pathways may drive 
niacin’s vascular benefit. Furthermore, several lines of evidence suggest that niacin can 
promote vascular health and reduce the progression of atherosclerosis, independent of its 
lipid lowering effects as no changes in plasma lipids levels were observed (Wu et al., 
2010; Lukasova et al., 2011; Digby et al., 2012b).  
Niacin treatment has been shown to reduce systemic inflammation in patients with CVD 
independent of changes in lipid levels, suggesting non-lipoprotein mediated anti-
inflammatory effects of niacin (Ridker et al., 1997, 2000; Kuvin et al., 2006). Through 
activation of GPR109A in adipocytes, niacin has been shown to inhibit secretion of pro-
inflammatory molecules such as TNFα, MCP-1, cytokines and fracaline limiting the 
contribution of these systemic inflammatory molecules to atherosclerosis (Digby et al., 
2010). GPR109A expression has been confirmed in monocytes and macrophages (Ahmed 
et al., 2009) and niacin, via GPR109A activation, has been shown to reduce monocyte 
adhesion to EC, reducing the pro-inflammatory state (Tavintharan et al., 2011). Niacin 
has also been shown to reduce the expression of MCP-1 and thus inhibit recruitment of 
neutrophils and macrophages to atherosclerotic plaques (Wu et al., 2010; Lukasova et al., 
2011). More recently, Si et al. (2014) demonstrated, both in vitro and in vivo, that niacin 
exerted its anti-inflammatory effects via downregulated NF-κB signaling pathways (Si et 
al., 2014).  
Niacin can also act as an antioxidant, protecting EC from oxidative stress. Treatment of 
coronary artery EC with niacin resulted in an upregulation of hemeoxygenase-1 (HO-1) 
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and resultant decrease in TNFα-mediated endothelial inflammation and oxidative stress 
(Wu et al., 2012a). HO-1 has been consistently associated with clinical benefit in many 
pathological diseases, including CVD.  Work by Ganji et al. (2009) has shown that niacin 
treatment increased endothelial NADPH and reduced glutathione which was associated 
with a reduction in ROS production and EC oxidative stress. Furthermore, in 
dyslipidemic patients, with low levels of HDL and hypercholesterolemia, treatment with 
niacin significantly decreased serum thiobarbituric acid and lipid peroxidases resulting in 
significantly reduced oxidative stress (Hamoud et al., 2013). 
Several studies exist to support the concept that niacin can directly improve EC function 
to provide a vascular benefit, independent of its lipid lowering effects. Niacin treatment 
improved angiogenesis following ischemic stroke, which was associated with increased 
expression of VEGF and increased PI3K activity (Chen et al., 2009; Shehadah et al., 
2010). In diabetic mice, independent from changes in plasma lipids, niacin increased 
blood flow following peripheral ischemia, enhanced endothelial progenitor cell 
mobilization and improved revascularization in a NO-dependent manner (Huang et al., 
2012). In rabbits, niacin protected against endothelial dysfunction noted by increased 
vasodilation, decreased expression of VCAM-1 and MCP-1 and inhibition of vascular 
inflammation (Wu et al., 2010). Recent work from our lab has demonstrated that niacin 
promotes HMVEC tube formation as well as enhances revascularization and functional 
recovery in diet-induced obese mice following ischemic injury (Hughes-Large et al., 
2014; Pang et al., 2016).  
Results from animal models suggesting that niacin directly improves EC function, 
independent of lipid lowering effects, are supported by human clinical studies. Niacin 
treatment significantly improved flow-mediated dilation (FMD) of the brachial artery in 
patients with T2DM (Hamilton et al., 2010) and metabolic syndrome (Thoenes et al., 
2007), without changes in lipid profiles. More recently, in a small clinical trial, a seven 
day treatment with niacin was enough to improve FMD, without altering lipid levels 
(Nasser Figueiredo et al., 2014). Furthermore, increased dietary niacin intake was 
associated with improved endothelial function as measured by FMD in the brachial artery 
and reduced oxidative stress (Kaplon et al., 2014). A recent meta-analysis, found that 
niacin significantly improved endothelial dependent vasodilation without changes in lipid 
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parameters and the effect was more prominent in primary prevention of atherosclerotic 
CVD (Sahebkar, 2014). Finally, niacin treatment has been shown to significantly reduced 
coagulation factors in patients with PVD that may have been associated with the reduced 
CVD morbidity in these patients (Chesney et al., 2000). Further understanding of the 
pleotropic effects of niacin, including promotion of vascular function and regeneration, 
outline an important step in determining the clinical use of niacin for the treatment of 
PVD during obesity and metabolic syndrome.    
1.5 Vitamin D and Vascular Function  
Historically, vitamin D has largely been recognized for its significant role in bone and 
mineral homeostasis. Recently however, vitamin D supplementation has gained much 
attention as a possible therapeutic option for CVD as several preclinical and 
epidemiological studies have demonstrated an association between low levels of 
circulating vitamin D and increased risk of CVD (Forman et al., 2007, 2008; Holick, 
2007; Wang et al., 2008a). Moreover, vitamin D deficiency has been identified as an 
independent risk factor for all-cause CVD morbidity and mortality (Brøndum-Jacobsen et 
al., 2012; Kojima et al., 2014). Consequently, widespread supplement use for the 
promotion of vascular health has increased, with the consumption of vitamin D 
supplements consistently rising (Pludowski et al., 2018). However, it remains unclear 
whether widespread vitamin D supplementation for the promotion of vascular health is 
actually beneficial.  Moreover, current dietary reference intakes and supplementation 
doses of vitamin D are based on the beneficial effects for the prevention of skeletal 
diseases such as rickets, osteomalacia, and fractures (Ross et al., 2011; Cashman & 
Kiely, 2014) where evidence is lacking in regards to supplemental doses associated with 
improved cardiovascular health (Pilz et al., 2016). 
Vitamin D is a fat soluble vitamin and exists in two dominant forms, vitamin D2 
(ergocalciferol), synthesized by invertebrates and plants, and D3 (cholecalciferol), that is 
naturally present in foods and endogenously photosynthesized in the skin in response to 
ultraviolet B radiation (Holick, 2003). Vitamin D itself is actually biologically inactive 
and requires two hydroxylation reactions in order to be biologically active (Bikle, 2014). 
The first hydroxylation reaction occurs in the liver where vitamin D is converted to 25-
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hydroxyvitamin D [25(OH)D],  which in then converted into the active form, 1α,25-
dihydroxyvitamin D3 [1α,25(OH)2D3], by 1α-hydroxylation that occurs primarily in the 
kidney (Bikle, 2014). Although the kidney is the primary site of the final hydroxylation 
step, this process can occur at various extra-renal sites within the body including skin 
cells, endothelial cells, pancreatic islet cells and monocytes/macrophages (Norman, 
2008). Finally, 1α,25(OH)2D3 can enter target cells and interact with the ligand-binding 
domain of the vitamin D receptor (VDR) in the cytoplasm (Norman, 2008). VDR is 
almost ubiquitously expressed and has been identified on various cardiovascular cells 
types including cardiomyocytes (Nibbelink et al., 2007), endothelium (Merke et al., 
1989), vascular smooth muscle cells (VSMC) (Wu-Wong et al., 2006) and myeloid cells 
(Wong et al., 2014). Following activation, VDR translocates to the nucleus and 
heterodimerizes with the retinoid X receptor (RXR). The VDR-RXR heterodimer can 
then act as a transcription factor to regulate gene expression by binding directly to 
vitamin D response elements (VDRE) (Whitfield et al., 1995). It has been estimated that 
VDR regulates approximately 3% of the genome (Carlberg, 2003), including processes 
important to cardiovascular physiology and pathology, such as proliferation, cellular 
differentiation, apoptosis and angiogenesis (Zittermann, 2014; Christakos et al., 2016). In 
addition to genomic regulation, vitamin D can also interact with VDR localized in 
caveolae of the plasma membrane and elicit rapid, nongenomic, responses that include 
activation of second messengers, rapid opening of calcium channels  and activation of 
signaling molecules (Norman, 2008). It has been suggested that both genomic and 
nongenomic responses of vitamin D are interrelated and  may further modulate, or cross 
talk, between the two signaling pathways (Norman, 2008). 
Several pathways and cell types that are relevant to cardiovascular physiology are 
influenced by vitamin D and may help to explain the role of vitamin D deficiency in the 
pathogenesis of CVD. Vitamin D has been proposed to reduce hypertension through the 
suppression of renin-angiotensin-aldosterone-system (RAAS) (Li et al., 2002). In vitro 
studies have confirmed that 1α,25(OH)2D3 is a potent negative regulator of renin 
transcription by blocking the cAMP response element in the renin gene promoter (Yuan 
et al., 2007). In addition, mice lacking VDR have increased levels of renin (Li et al., 
2004). Over activation of the RAAS pathway leads to blood vessels constriction, 
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contributing to hypertension and cardiac hypertrophy. Vitamin D may also protect against 
hypertension through its suppressive effects on parathyroid hormone (PTH) synthesis 
(Lee et al., 2008; Wallis et al., 2008; Lips, 2012), as increased serum concentrations of 
PTH are associated with increased risk for cardiovascular events including calcium 
overloading of cardiomyocytes (Watson et al., 1997; Andersson et al., 2004), increased 
oxidative stress, endothelial dysfunction (Gambardella et al., 2018) and myocardial 
hypertrophy (Saleh et al., 2003; Chen et al., 2011). Experimental studies have also 
suggested that vitamin D may protect against atherosclerosis by inhibiting foam cell 
formation and increasing cholesterol efflux (Oh et al., 2009; Yin et al., 2015).  
Furthermore, VDR activation in VSMC results in upregulation of endothelin receptor 
type B and decreased oxytocin receptor expression to favour vessel relaxation (Bukoski 
et al., 1989). Lastly, vitamin D may promote EC repair by inducing VEGF expression in 
VSMC (Cardús et al., 2006; Wu-Wong et al., 2006). 
As mentioned above, several cell types have the vitamin D microendocrine system that 
allows for extra-renal synthesis of 1α,25(OH)2D3, including EC (Merke et al., 1989). A 
direct effect of VDR in the regulation of endothelial function was recently demonstrated 
by Ni et al. (2014) using endothelial-specific VDR knockout mice. Deletion of VDR 
resulted in impaired vessel relaxation accompanied by reduced eNOS expression and 
augmented blood pressure response to AngII (Ni et al., 2014). Several studies have 
demonstrated beneficial effects of vitamin D supplementation on vascular endothelial NO 
production (Molinari et al., 2011; Uberti et al., 2014; Martínez-Miguel et al., 2014). 
Activation of endothelial VDR has been shown to increase production of NO through 
p38/Akt-modulated eNOS activation (Molinari et al., 2013). Additionally, experimental 
work performed in mice with functionally inactive VDR displayed lower NO 
bioavailability and decreased eNOS expression, which was associated with endothelial 
dysfunction and increased arterial stiffness (Andrukhova et al., 2014). Treatment of 
HUVECs with vitamin D was able to improve NO production by reducing the deleterious 
effect of advanced glycation end products (Talmor et al., 2008). Wong et al. (2010) 
confirmed that treatment with vitamin D was associated with improved EC functions 
noted by reduced blood pressure and EC vasoconstriction in the aorta of hypertensive 
rats. 
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Vitamin D may protect EC function through antioxidant pathways. In diabetic rats, 
treatment with the vitamin D analog, 22-oxacalcitriol, reduced EC NADPH oxidase 
expression, which was associated with reduced EC dysfunction in diabetic rats (Hirata et 
al., 2013). Addition of 1α,25(OH)2D3  to culture media was able to prevent hypoxia 
induced downregulation of CuZn-superoxide dismutase expression in EC  (Zhong et al., 
2014). Furthermore, Polidoro et al. (2013) have shown that treatment of HUVECs with 
vitamin D induced MEK/ERK-Sirt-1 signalling pathway to decrease H2O2 oxidant injury. 
A more recent study found that treatment of HUVECs with 1α,25(OH)2D3  led to 
decreased ROS production, increased expression of the known antioxidant, glutathione, 
and reversed the dysfunctional phenotype (Kanikarla-Marie & Jain, 2016). Vitamin D 
may also protect against EC oxidative stress by reducing apoptotic gene expression, 
while simultaneously enhancing autophagy by ERK 1/2 and Akt activation (Uberti et al., 
2014).  
Vitamin D may improve EC function by downregulating inflammation, as treatment with 
1α,25(OH)2D3 has been associated with decreased expression of various inflammatory 
factors, such as TNFα, IL-6, IL-10 and NF-κB in EC (Martinesi et al., 2006). Suzuki et 
al. (2009) showed that treatment of coronary EC with vitamin D inhibited TNFα-
mediated NF-κB activation and expression of E-selectin. Follow-up studies showed that 
vitamin D also inhibited TNFα-mediated expression of VCAM-1 and IL-8 in coronary 
EC (Kudo et al., 2012). In HUVECs, treatment with vitamin D inhibited LPS-induced 
NF-κB activation and expression of IL-6 and IL-8 (Equils et al., 2006). Lastly, treatment 
of HUVECs with vitamin D has been shown to reduce monocyte adhesion to HUVECs, 
possibly through decreased expression of MCP-1 and ICAM-1 (Martinesi et al., 2006; 
Kanikarla-Marie & Jain, 2016).  
Taken together, there is compelling evidence linking vitamin D and EC function, raising 
the intriguing possibility that a causal relationship exists between vitamin D deficiency 
and CVD pathogenesis. However, establishing the clinical relevance of vitamin D 
supplementation and cardiovascular benefit in humans has been a challenge. In fact, 
several interventional studies examining the effect of vitamin D repletion on EC function 
in humans have shown conflicting results. Vitamin D supplementation improved EC 
function in T2DM patients with low vitamin D levels (Sugden et al., 2008) and improved 
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EC function in obese adults as noted by increased FMD (Harris et al., 2011). In stroke 
patients, short term vitamin D supplementation improved EC function, noted by 
increased FMD (Witham et al., 2012). Additionally, a recent meta-analysis found that 
vitamin D supplementation was associated with improved EC function in a subgroup of 
patients with diabetes (Hussin et al., 2017). Conversely, vitamin D supplementation had 
no significant effects on vascular EC function in T2DM patients following 12 weeks of 
oral supplementation (Yiu et al., 2013). Vitamin D supplementation also had no effect on 
vascular function in various populations with low levels of vitamin D (Longenecker et 
al., 2011; Witham et al., 2013). Lastly, recent meta-analyses (Jenkins et al., 2018) and 
primary end point analyses from the VITamin D and OmegA-3 TriaL (VITAL) (Manson 
et al., 2019) indicate no general cardiovascular benefit associated with vitamin D 
supplementation. Discrepancy between results may be attributed to phenotypic 
characteristics of study participants (Hussin et al., 2017; Bellan & Marzullo, 2018), 
outlining the importance of identifying the role of vitamin D in various patient 
populations to determine which cohort may have the most cardiovascular benefit, if at all, 
from vitamin D supplementation.  
Few studies exist evaluating the effects of vitamin D supplementation on processes of 
revascularization for the prevention and/or intervention of PVD in humans. 
Neovascularization is a complex process requiring the coordinated proliferation and 
migration of EC, and their assembly into new, functional vasculature. Furthermore, the 
effects of vitamin D on this process appear to be context-dependent. During tumour 
progression, vitamin D is apparently anti-angiogenic (Saghiri et al., 2017; Jamali et al., 
2018); while in the setting of vascular injury, it can promote vessel regeneration, and 
restoration of blood pressure control (Ni et al., 2014; Wong et al., 2014; Hussin et al., 
2017). However, in the setting of obesity and metabolic syndrome, the effects of vitamin 
D supplementation on peripheral ischemia, a characteristic of PVD, and the vascular 
regenerative mechanisms involved, are unclear.  
1.6 Traditional, Complementary and Alternative Medicine  
Several lines of evidence exist to show that people living with chronic conditions, 
especially those with obesity-related diseases, are often turning to use of Traditional, 
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Complementary and Alternative Medicines (TCAMs) (Falci et al., 2016), including 
multivitamins (Yeh et al., 2006; Saydah & Eberhardt, 2006; Bailey et al., 2012). 
Moreover, studies show that individuals with two or more chronic conditions, a common 
scenario when considering metabolic disease, are more likely to use TCAM (Sirois, 2008; 
Jacobson et al., 2009), with multivitamins being the most frequently used (Gahche et al., 
2011). Despite the popularity of multivitamins, it is not clear whether this approach is 
beneficial. Furthermore, the latest update from the United States Preventative Services 
Task Force (USPSTF) has concluded that, “The current evidence is insufficient to assess 
the balance of benefits and harms of single or paired nutrient supplements for the 
prevention of CVD” (Moyer & USPSTF, 2014). Understanding the effects of co-
supplementation, such as combining vitamin D and niacin supplementation, for the 
promotion of vascular health will help to guide future recommendations for nutritional 
and/or TCAM strategies for the prevention of CVD.  
Combining vitamin D supplementation with other vitamins, such as niacin,  may offer 
additive or synergistic effects on endothelial cell function and vascular regeneration as 
they signal through separate endothelial cell receptors, GPR109A (Hughes-Large et al., 
2014) and VDR (Ni et al., 2014), respectively. Both niacin and vitamin D appear to have 
overlapping pleotropic effects in promoting endothelial cell functions including increased 
NO signalling, antioxidant capacity and anti-inflammatory signalling. Combining 
vitamins may offer additive or synergist effects, as previous literature has suggest that 
combination of nutrients, such that would be found in whole foods offer additional 
benefit compared to single nutrients and isolated supplements (Liu, 2003; Jacobs et al., 
2009). The extent of the combined effects may depend on receptor expression levels as 
well as the receptor distribution on the different vascular cell types involved in vascular 
regeneration as well as their downstream signalling pathways and targets.  Currently, the 
effect of combining vitamin D and niacin supplementation on vascular regeneration has 
not been tested. Moreover, understanding the interactions between these vitamins on this 
process is particularly relevant to the rise in popularity of TCAMs and widespread use of 
multivitamin supplements for the promotion of vascular health (Sesso et al., 2012; Bailey 
et al., 2013; Kantor et al., 2016).  
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In Canada, a population of interest when considering the use of TCAMs for the 
management of obesity and associated comorbidities is Canada’s Indigenous community. 
There is a disproportionate burden of obesity-related diseases, including metabolic 
syndrome, diabetes and CVD, on Canada’s Indigenous population with the prevalence of 
diabetes for on-reserve Indigenous people estimated at 17.2% compared to only 5% for 
non-Indigenous Canadians (Rice et al., 2016). Current intervention strategies have shown 
limited success for Indigenous communities as strategies have failed to address culturally 
relevant interventions and account for Indigenous conceptualization of health and 
wellness (Rice et al., 2016; Murdoch-Flowers et al., 2017). Multiple research studies 
have shown that a person’s beliefs towards medication and disease differ across cultures 
and can be influenced by multiple factors including historical factors, such as 
colonization, that may impact an individual’s beliefs and/or attitude towards medication 
and their acceptance of treatment interventions (Simoni et al., 2012; McQuaid & Landier, 
2018). For these reasons, there have been multiple calls to action for culturally relevant 
intervention and prevention strategies for obesity and T2DM in Canada’s Indigenous 
communities (Smylie et al., 2009; McNamara et al., 2011; Saini & Quinn, 2013).  
Indigenous scholars have proposed to include a blending of traditional or culturally 
relevant healing, such as TCAM therapy, with Western medicine, effectively bridging the 
gap between Indigenous science and Western science (Massey & Kirk, 2015; Leung, 
2016). This highlights the importance of studying the effects of natural, diet-derived 
compounds, such as niacin and vitamin D on vascular regeneration in the setting of 
obesity. Further understanding of the effects of these vitamins can help guide TCAM as 
well as nutritional recommendations for the prevention and/or intervention of PVD in 
obese and diabetic Indigenous people failing to respond or adhere to Westernized 
treatments. 
1.7 Objectives and Hypothesis 
Rationale 
PVD is a common downstream complication associated with obesity and metabolic 
syndrome (Garg et al., 2014). Current therapies for PVD are limited and fail to target 
endogenous revascularization of the ischemic tissue (Farber & Eberhardt, 2016). 
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Furthermore, there is a disproportionate burden of obesity-related diseases, including 
metabolic syndrome, CVD, and PVD on Canada’s Indigenous population, with current 
intervention strategies showing limited success in this patient population (Rice et al., 
2016; Murdoch-Flowers et al., 2017). Thus, studies are needed to identify compounds, 
including culturally relevant TCAMs such as natural diet-derived compounds, that 
support the formation of new blood vessels in ischemic tissues.  
Endothelial dysfunction has been identified as a surrogate marker for the development of 
PVD (Campia et al., 2012; Kim et al., 2012) and highlights an important target for 
therapeutic intervention/prevention strategies. Recent studies have shown an association 
between low levels of vitamin D and increased risk for CVD (Forman et al., 2007; Wang 
et al., 2008b; Afshari et al., 2015; Roy et al., 2015), raising the intriguing notion that 
vitamin D supplementation may be beneficial for the promotion of vascular health. 
However, the effects of vitamin D on EC function and vascular regeneration have stirred 
much controversy and appear to be context-dependent. Whether vitamin D 
supplementation can improve EC function and promote vascular regeneration under 
lipotoxic conditions observed during obesity and metabolic syndrome is unclear. 
Furthermore, the effects of combining vitamin D with other TCAMs or vitamins, such as 
niacin, on endothelial function under lipotoxic conditions are unknown. Figure 1.2 
summarizes the pathogenesis of endothelial dysfunction during obesity and metabolic 
syndrome and identifies potential mechanisms by which vitamin intervention may 
promote EC function.   
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Figure 1.2. Summary of endothelial dysfunction and potential therapeutic 
intervention strategies to protect endothelial function during obesity and metabolic 
syndrome. 
During obesity and metabolic syndrome (1) there is accumulation of lipids in adipocytes 
(2). Once adipocyte capacity is exceeded uncontrolled, dysregulated lipolysis occurs (3), 
releasing excess fatty acids into circulation (4). Endothelial cells are continuously 
exposed to high levels of circulating lipids as they comprise the inner most layer of 
vasculature. Endothelial cells lack the metabolic programming to process excess fatty 
acids. Excess palmitate, an abundant dietary saturated fatty acid, can overwhelm the 
ability of a cell to store fatty acids in lipid droplets or to catabolize them through β-
oxidation in mitochondria. This can result in production of reactive oxygen species 
(ROS) and ER stress, resulting in endothelial dysfunction and eventual death, through a 
process termed lipotoxicity. Palmitate can also readily be incorporated into the ER lipid 
membrane, resulting in impaired membrane structure and integrity. Oxidative stress and 
ER stress result in release of calcium from the ER further contributing to mitochondrial-
mediated cell death (5). Niacin and vitamin D may be useful therapeutic compounds 
against endothelial dysfunction as they are known to promote normal endothelial function 
(6). 
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Hypothesis 
Supplementation of vitamin D alone and in combination with niacin, will improve EC 
angiogenic function and promote vascular regeneration under lipotoxic conditions that 
occur during obesity and metabolic syndrome. 
Objectives  
The specific objectives of this thesis were to: 
1) Determine whether vitamin D supplementation alone and in combination with 
niacin, improves in vitro HMVEC angiogenic function in the presence of high 
palmitate. 
2) Determine global changes in HMVEC gene expression induced by 
supplementation of vitamin D or niacin during exposure to high palmitate in order 
to identify and compare genes and pathways that may underlie any angiogenic 
responses.  
3) Determine whether vitamin D supplementation alone and in combination with 
niacin, improves functional recovery and neovascularization following femoral 
artery ligation and excision. 
Relevance to Disease 
Endothelial dysfunction has been identified as a surrogate marker for the development of 
PVD and highlights an important target for therapeutic intervention/prevention strategies 
(Nosova et al., 2015; Farber & Eberhardt, 2016). Therefore, it is important to develop 
better understanding of therapeutic agents that may be useful interventions against 
endothelial dysfunction and promote EC maintence under high fat settings. In light of the 
recent popularity of vitamin D supplementation for cardiovascular health, determining 
whether vitamin D can promote EC function and improve functional recovery, under a 
high fat setting, is important in determining future clinical applications of vitamin D. 
Furthermore, understanding the effects of co-supplementation of vitamin D with niacin is 
an important step in addressing the rise in popularity of TCAMs and widespread use of 
multivitamin supplements for the promotion of vascular health. The work described in 
this thesis will help to better understand the effect of vitamin D alone and in combination 
with niacin, on the vasculature during lipotoxic conditions and may help guide future 
therapeutic and nutritional recommendations for obese patients with PVD. 
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Chapter 2  
2 Materials and Methods 
2.1 Cell Culture and Treatments 
For all cell culture experiments, primary human dermal microvascular endothelial cells 
(HMVEC) isolated from small vessels within dermal tissue were used as they are a close 
representation of cells likely to initiate vascular regeneration in the tibialis anterior 
muscle under low oxygen conditions during peripheral limb ischemia (Shireman, 2007). 
Cells from a single adult donor were obtained from Lonza (Cat.#CC-2811; Walkerville, 
MD USA) and maintained in Medium 199 (Life Technologies) supplemented with EGM-
2-MV SingleQuots (Lonza). Cells were grown on 100 mm culture dishes, at 37°C and 
5% CO2 and growth medium was changed every 2-3 days. Cells were used between 
passage 4 and 10 and subcultured at 80% confluence using trypsin-EDTA solution 
(Lonza). 
For high fat (lipotoxic) conditions, cells were exposed to medium supplemented with the 
saturated fatty acid palmitate at a concentration of 0.5 mM. A stock solution of 20 mM 
palmitate was prepared by saponification using 0.01 M NaOH and heated to 70°C for 30 
minutes. Palmitate stock solutions were complexed to 30% bovine serum albumin (BSA) 
at a molar ratio of 2:1 prior to the addition of growth medium to reach a final fatty acid 
concentration of 0.5 mM (Hughes-Large et al. 2014). The concentration of palmitate used 
reflects a high physiological to pathophysiological concentration that would be observed 
during metabolic disease (Gordon, 1960; Soriguer et al., 2009). Growth medium 
supplemented with fatty acid free 30% BSA alone was used as control.  
To establish dose response, growth medium was supplemented with increasing 
concentrations of either vitamin D (1,25-dihydroxyvitamin D3; Sigma Aldrich; 0 - 100 
nM) solubilized in dimethyl sulfoxide (DMSO) and stored under N2, niacin (Sigma 
Aldrich; 0 - 100 μM) solubilized in cell culture grade water at room temperature, a 
combination of vitamin D and niacin (0 - 100 nM and 0 - 100 μM, respectively), or 
vehicle (DMSO). Matrigel assays of endothelial tube formation and stability, described 
below, were used to evaluate dose response. For all subsequent vitamin treatments, 
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growth medium was supplemented with 10 µM niacin, and/or 10 nM vitamin D. 
Concentration ranges selected for niacin and vitamin D treatments are reflective of 
physiological plasma concentrations that can be achieved following oral administration of 
high dose niacin (2-3 g), which have been shown to be approximately 10 µM - 240 µM 
within 8 h of dosing (Menon et al., 2007), or recommended supplemental dose vitamin D 
(1000 IU), which are 10 - 25nM (Lorvand Amiri et al., 2017). Initially, the effects of 
vehicle treatments (water and DMSO) under both BSA and palmitate conditions were 
compared to confirm that there were no effects. For all subsequent experiments a 
conservative approach was taken and DMSO (2 μL/mL of media) was used as the vehicle 
control. 
2.2 Tube Formation and Stability Assays  
Prior to cell harvesting, a pre-chilled 96-well plate was coated with 40 µL/well of growth 
factor-replete Matrigel basement membrane Matrix (BD Biosciences). The plate was 
incubated for 30 minutes at 37°C before cells were plated to allow for solidification of 
Matrigel. HMVEC were harvested with EDTA-trypsin, counted using a hemocytometer, 
resuspended in growth medium and seeded onto matrigel coated plates at a density of 
37,500 cells/cm
2
. Cells were treated with corresponding treatments in order to establish a 
dose-response. Cells were incubated at 37°C and 5% CO2 to allow endothelial tubes to 
form. Resulting tube networks were imaged by light microscopy at 18 hours for tube 
formation, and at 24 and 42 hours for tube stability. A tube was defined as an apparently 
three-dimensional, elongated structure stretching between branch points, with a width 
large enough along its entire length to permit the passage of an erythrocyte (Borradaile & 
Pickering, 2009a). For each condition, EC tube formation and stability were evaluated by 
measuring the total tube length for the entire well at all three time points using ImageJ 
software. Dose response was evaluated by comparing total EC tube lengths at 18, 24 and 
42 h of incubation between the various concentrations of each treatment. Tube stability 
was evaluated by areas under the curve assessing total tube length over time from 18 
hours to 42 hours, where a larger value indicates less tube degradation over the 24 hours 
following tube formation and thus improved tube stability.  
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2.3 HMVEC Cytotoxicity  
Cytotoxicity was assessed by MTT [3-(4,5-Dimethylthiazol-2-Yl)-2,5-
Diphenyltetrazolium Bromide] assays. HMVEC were seeded onto 96-well plates at a 
density of 31,250 cells/cm
2
 and incubated for 5-6 hours to allow for adhesion to the plate. 
Cells were incubated with corresponding treatments in triplicate for 16 hours. Ten µL of  
MTT (5 mg/mL of PBS) was added to each well and incubated for 3 hours, followed by 
addition of 100 µL/well of MTT lysis buffer. Plates were covered in aluminum foil and 
incubated at room temperature overnight. Absorbance was quantified 
spectrophometrically at a wavelength of 595 nm. 
2.4 Cell Viability 
HMVEC viability was assessed using trypan blue assays. HMVEC were seeded onto 6-
well plates at a density of 2,500 cells/cm
2
. Cells were incubated for 16 hours in 
corresponding treatments. Following incubation, cells were harvested using 
trypsin/EDTA. Fifty µL of resuspended cells were mixed with 50 µL of trypan blue. A 
hemocytometer was used to count cells. Dead cells were detected by blue staining and 
viable cells were detected by absence of blue staining. Percent viability was calculated 
using the equation:   
Viable cells per mL/total cells per  mL x 100  
2.5 Global Gene Expression  
HMVEC were grown to 80-90% confluence in 100 mm dishes and treated for 16 hours 
with two or three dishes combined per treatment. Cells were harvest by direct lysis using 
500 µL of Buffer RLT added to every dish and lysed using QIAshredders (QIAGEN). An 
equal volume of 70% ethanol was added to the lysate, mixed by pipetting and transferred 
to an RNeasy spin column and centrifuged for 15 seconds at 8,000 x g. Flow through was 
discarded and 700 µL Buffer RW 1 was added to the spin column and centrifuged for 15 
seconds at 8,000 x g. Flow through was discarded and 500 µL Buffer RPE was added to 
the spin column and centrifuged for 15 seconds at 8,000 x g. Flow through was discarded 
and another 500 µL of Buffer RPE was added to the spin column and centrifuged for 2 
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minutes at 8,000 x g. The sample was then dried by centrifugation for an additional 1 
minute at > 8,000 x g. RNA was extracted from the spin column by addition of 45 µL of 
RNase-free water and centrifuged for 1 minute at 8,000 x g. All samples were stored at -
80°C.   
RNA concentration and purity were measured by NanoDrop (Thermo Scientific). 
Samples were diluted to a concentration of 200 ng/µL in nuclease-free water. All sample 
labeling and GeneChip processing were performed at the London Regional Genomics 
Centre (Robarts Research Institute). 
RNA quality was assessed using the Agilent 2100 Bioanalyzer (Agilent Technologies) 
and the RNA 6000 Nano kit (Caliper Life Sciences). Following assessment, end labeled 
single stranded complementary DNA was prepared from 200 ng of total RNA and 
hybridized, for 16 hours at 45°C, to Human Gene 2.1 ST arrays, as described in the 
Affymetrix Technical Analysis Manual.  
All liquid handling steps were performed by GeneChip Fluidics Station 450 and 
GeneChips were scanned with the GeneChip Scanner 3000 7G (Affymetrix) controlled 
by Command Console v3.2.4. Microarray probe data were imported into Partek 
Genomics Suite v6.6 using the RMA algorithm (Irizarry et al., 2003).  
Partek was used to determine gene level ANOVA p-values and fold changes. Filtered 
gene lists were generated for expression changes of greater than 2.0-fold and having a p-
value of less than 0.05. Lists of genes exhibiting at least a 2.0-fold change in expression 
with a p-value less than 0.05 were used for gene ontology (GO) and KEGG pathway 
enrichment analyses. Over-represented transcripts were also imported into the open-
source Reactome curated pathway data base (v58) (http//www.reactome.org/) for further 
analyses. Pathway overview schematics, indicating significantly represented (p < 0.05) 
nodes (pathways) and relationships between nodes were generated for each list of 
differentially expressed genes.  
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2.6 qRT-PCR  
cDNA was synthesized from RNA samples using a High Capacity RNA-to-cDNA kit 
(Applied Biosystems) or TaqMan Advanced miRNA cDNA Synthesis kit (Applied 
Biosystems) following the manufacturer’s protocol. For cDNA synthesis, RNA samples 
were mixed with 2X RT Buffer Mix, 20X Enzyme Mix and nuclease-free water in 
microfuge tubes. Reverse transcription of RNA samples was performed for 60 minutes at 
37°C, followed by 5 minutes at 95°C, then cooling of the samples to 4°C. For miRNA 
cDNA synthesis, RNA samples underwent four different reaction steps. First, a poly(A) 
tailing reaction was performed. Poly(A) reaction components were mixed in a 1.5 mL 
microfuge tube. Ten ng of RNA sample was mixed with 3 µL poly(A) reaction mixture. 
For polyadenylation, samples were incubated at 37°C for 45 minutes, and then the 
reaction was stopped by incubating at 65°C for 10 minutes and cooled to 4°C. 
Immediately following, an adaptor ligation reaction was performed. Adapter ligation 
components were mixed in a 1.5 mL microfuge tube  and 10 µL of ligation reaction mix 
was added to the microfuge tube containing the poly(A) tailing reaction product. For 
ligation, samples were incubated at 16°C for 60 minutes and cooled to 4°C. Immediately 
following, reverse transcription reaction mixture was prepared  and 15 µL of the reverse 
transcription reaction mixture was added to the microfuge tube containing the adaptor 
ligation reaction product. For reverse transcription, samples were incubated at 42°C for 
15 minutes then the reaction was stopped by incubating at 85°C for 5 minutes and cooled 
to 4°C. Following, a miR-amplification reaction was performed. MiR-amplification 
reaction components were mixed in a 1.5 mL microfuge tube and 45 µL miR-
amplification reaction mixture was mixed with 5 µL of the reverse transcription reaction 
product in a new microfuge tube. For miR-amplification, the samples were incubated at 
95°C for 5 minutes to allow for enzyme activation and then run for 14 cycles with a 95°C 
denature step for 3 seconds, followed by 30 seconds of annealing at 60°C. The reaction 
was then stopped by incubating at 99°C for 10 minutes and cooled to 4°C.   
Real-time qualitative polymerase chain reaction (qRT-PCR) was performed using 
reagents from Applied Biosystems. Taqman primers for GAPDH control, CXCL8, 
DDIT3, IL1A, HMOX1, SMOX, BMX, MANF, APOLD1, BAMBI, CEBPB, CDK1, 
MCM5, CYP24A1, pri/pre-miR126, miR126-5p and miR126-3p were obtained from 
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Applied Biosystems. Both cDNA and miRNA cDNA samples were diluted with 
nuclease-free water to 25 ng/µL. Reaction components were mixed according to the 
TaqMan Gene Expression Assays and TaqMan Advanced miRNA Assays Reference 
Cards. Samples (20 µL) were plated in triplicate into a 384-well reaction plate. Plates 
were sealed, briefly centrifuged and loaded into the ViiA 7 qRT-PCR system (Applied 
Biosystems). The plate was run for 40 cycles with a 15 second denature at 95°C followed 
by a 1 minute anneal/extend step at 60°C. Cycle threshold (Ct) values were used to 
calculate ∆∆Ct values and expression fold changes (2-∆∆Ct) for each sample. GAPDH was 
used as an endogenous control for all reactions.  
2.7 Growth Rate 
HMVEC were seeded onto 6-well plates at a density of 2,500 cells/cm
2
. Cells were 
incubated with corresponding treatments for 16 hours, harvested using trypsin/EDTA and 
counted using a hemocytometer. Population doublings per day were calculated for each 
treatment using the equation: 
 log10(number of cells harvested) – log10(number of cells seeded) × (log102)
-1
 
2.8 Mouse Model  
In order to induce obesity and characteristics of metabolic syndrome, 5 week old male 
129S6/SvEv mice were fed a western diet containing 42% calories from fat, 15.2% 
calories from protein and 42.7% calories from carbohydrates (Envigo, Toronto, ON) ad 
libitum for a total of 17 weeks. Figure 2.1 outlines the mouse experimental procedure. 
Figure 2.1. Outline of mouse experimental model and treatment. 
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After 15 weeks of feeding, mice underwent right hind limb femoral and saphenous artery 
ligation and excision surgery. Mice were anesthetized using a combination of 
intraperitoneal (i.p.) ketamine (150 mg/kg) and xylazine (5 mg/kg). A small incision was 
made in the right hind limb to expose the femoral artery. The proximal end of the femoral 
artery and the distal end of the saphenous artery were ligated using silk sutures. Mice 
were administered one i.p dose of meloxicam (1 mg/kg), followed by a second dose 24 
hours post-surgery. Following surgery, mice were randomized to one of four intervention 
treatments with vehicle, niacin (50 mg/kg), vitamin D (200 ng/kg), or niacin and vitamin 
D (50 mg/kg and 200 ng/kg, respectively) and received once daily i.p. injections for 2 
weeks (14 days) following surgery. To ensure complete solubilization of each treatment, 
the vehicle for niacin was sterile water (Pang et al., 2016), and the vehicle for vitamin D 
was sterile water:propylene glycol:ethanol (5:4:1, volumetric ratio) (Wong et al., 2014). 
Each mouse received sequential, individual injections of each solution on opposing sides 
of the peritoneal cavity. The dose of niacin approximates a human dose of 250 mg 
(Reagan-Shaw et al., 2008). The dose of vitamin D corresponds to the concentration 
found to improve HMVEC tube formation and stability (10 nM) from cell culture 
experiments performed in this study, and reflects increases in plasma concentrations 
achieved following oral administration of vitamin D (1000 IU) in obese humans with 
metabolic syndrome and fatty liver (Lorvand Amiri et al., 2017). Two experiments 
consisting of 16 mice each were staggered by one month to accommodate surgeries on all 
mice. A total of eight mice were assigned to each treatment group.  
Blood pressure and heart rate were taken pre- and post-surgery and measured with tail-
cuff plethysmography (CODA, Kent Scientific Corp, Torrington, CT, USA).  
Functional recovery of the hind limb was assessed on days 3, 9 and 15 post-surgery by 
gait analysis using a Catwalk system (Noldus) at the Neurobehavioural Core Facility at 
Robarts Research Institute. Mice were recorded as they traversed a glass walkway and the 
duration of contact for each paw was reordered to generate digital gait maps. Mean paw 
contact times were used to calculate hind limb use ratios of injured (right) to uninjured 
(left) limbs. A ratio of <1.0 indicates decreased use of the injured limb. Complete 
recovery of limb use is indicated by a hind limb use ratio of 1.0. Areas under the curve 
were calculated to assess functional recovery over the two-week treatment period.  
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On day 15 post-surgery, mice were sacrificed and blood, liver, pancreas, heart, and 
adipose tissues were harvested and weighed. The tibialis anterior, gastrocnemius, and 
adductor muscles were also isolated from each mouse. Plasma TG and cholesterol were 
determined by enzymatic, colorimetric assays (Roche Diagnostics). Blood glucose was 
determined using an Ascensia Elite glucometer (Bayer). Plasma insulin was measured 
using mouse ultrasensitive insulin enzyme-linked immunosorbent assay (ELISA, Alpco 
Diagnostic). Plasma liver enzymes (ALT and AST) were measured by the London Health 
Sciences Centre Core Laboratory. Liver cholesterol and triglycerides were determined by 
enzymatic, colorimetric assays (Roche Diagnostics/Wako Diagnostics). All plasma and 
tissue metabolic parameters, with the exception of AST/ALT measurements, were 
performed through the Metabolic Phenotyping Laboratory in Robarts Research Institute 
at Western University. Modified from Pang et al. (2016). Metabolic data was compared 
to previous observations of age-matched lean control 129S6 mice, fed a standard chow 
diet (Pang et al., 2016). 
2.9 Histology 
At sacrifice, tibialis anterior, gastrocnemius, and adductor muscles were isolated and 
immersed in zinc fixation buffer (0.1 mol/L Tris-HCl buffer (pH 7.4) containing 0.5 g/L 
calcium acetate, 5.0 g/L zinc acetate, 5.0 g/L zinc chloride) followed by paraffin 
embedding. A microtome was used to cut 5 μm serial cross sections at three equally 
spaced locations spanning the length of the tibialis anterior muscle. Four images per 
section were captured for a total of twelve high powered fields of view per muscle (one 
muscle per mouse) using an Olympus BX51 light microscope. All tissue processing, 
cutting, and staining was performed at the Molecular Pathology Core Facility (Robarts 
Research Institute).  
For determination of tibialis anterior muscle architecture, sections were stained with 
hematoxylin and eosin. Total myofiber and adipose tissue areas per section were 
calculated using a customized, automated ImageJ software protocol. Sections were 
manually analyzed, using ImageJ, to calculate areas of regenerating myofibers, identified 
by intense eosin staining and central nuclei, non-regenerating myofibers, identified by 
intense eosin staining and the presence of peripheral nuclei, and necrotic myofibers, 
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identified by pale eosin staining and absent nuclei (Pang et al., 2016). Ratios of 
regenerating to non-regenerating myofibers per mouse were calculated. Adipose areas 
were normalized to total section areas and reported as percentages. 
To determine vessel densities, sections were double immunostained for CD31 (BD 
Biosciences) and smooth muscle α-actin (αSMA) (Sigma Aldrich), sourced from rats and 
mouse clones 1A4, respectively. Hematoxylin was used as a counter stain (van der Veer 
et al., 2005; Frontini et al., 2011). Capillary and arteriole densities were determined by 
manually counting CD31
+
 vessels and αSMA+. Arteriole diameter frequencies were 
determined by automated analyses using a combination of ImageJ and MATLAB 
software that measured the diameter of every αSMA+ vessel across all images for each 
treatment group. Frequency distribution plots of vessel diameters for each treatment 
group were generated using GraphPad Prism 7.  
Tibialis anterior muscle inflammation was determined by immunostaining for the pan-
macrophage marker, F4/80 (Invitrogen, Thermo Fisher Scientific). Tibialis anterior 
muscle fibrosis was determined by Masson’s Trichrome staining. Total macrophage and 
collagen areas were quantified using a customized, automated ImageJ protocol. 
Inflammation (F4/80
+
) and fibrosis (collagen) areas were normalized to total section 
areas and reported as percentages. A fibrosis location score was determined for each 
mouse, to provide relative quantification of myofiber-associated collagen. Each of the 
four images per section was assigned a value of 1 if myofiber-associated collagen was 
present, so that the maximum value per section would equal 4. Then the average vale 
across sections for each mouse was calculated and multiplied by the percent collagen for 
that mouse. Thus, a higher score indicates greater presence of myofiber-associated 
collagen. 
2.10 Statistics 
All statistical analyses and generation of graphs were performed using GraphPad Prism 7 
(GraphPad Software, La Jolla, CA, USA), except for microarray analyses. Data in Figure 
3.1B,C were assessed by t-tests comparing PA vs. BSA within each treatment group. All 
remaining data were assessed using one-way ANOVA, followed by Tukey post-hoc tests. 
Differences in means were considered statistically significant at p<0.05. 
35 
 
 
Chapter 3  
3 Results  
3.1 Niacin and vitamin D improve HMVEC tube formation 
and stability in high palmitate 
Recently, vitamin D supplementation has gained much attention for the promotion of 
vascular health. However, effects of vitamin D on endothelial angiogenic processes 
appear to be disease-context dependent. During tumour progression, vitamin D is 
apparently anti-angiogenic (Saghiri et al., 2017; Jamali et al., 2018); while in the setting 
of vascular injury, several studies have demonstrated a beneficial effect of vitamin D 
supplementation on vascular endothelial cell functions (Hussin et al., 2017; Wong et al., 
2014; Ni et al., 2014). Combined supplementation with other vitamins, such as niacin, 
could also have additive or synergistic effects. Thus, we determined whether vitamin D 
supplementation in the absence or presence of niacin would improve HMVEC angiogenic 
processes under high palmitate conditions that would be observed during obesity and 
metabolic syndrome.  
We previously found that supplementation of culture medium with low-dose niacin (10 
µM) preserves HMVEC tube formation during high palmitate under both normoxic 
(Hughes-Large et al. 2014) and hypoxic conditions (Pang et al., 2016). We reproduced 
this earlier observation (Figure 3.1A) in order to compare the effects of vitamin D alone, 
and in combination with niacin, on tube formation during lipotoxic conditions. 
HMVEC tube formation on Matrigel was impaired after 18 hours of incubation in growth 
medium supplemented with the saturated fatty acid palmitate (Figure 3.1A-D).  Media 
supplemented with low doses of niacin (10 μM) alone, vitamin D (10 nM) alone, and the 
combination of niacin (10 μM) and vitamin D (10 nM) significantly increased HMVEC 
tube formation at 18 hours of incubation in high palmitate (Figure 3.1A, B, D). It was 
found that vitamin D at a concentration of 10 nM and niacin at a concentration of 10 μM 
were optimal concentrations for tube formation assays as higher concentrations offered 
no further benefit, and lower concentration were not as effective. In fact, Vitamin D at a 
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concentration of 100 nM was found to significantly decrease HMVEC tube formation at 
18 hours of incubation in high palmitate (Figure 3.1C), suggesting this concentration of 
vitamin D was becoming toxic to cells under lipotoxic conditions.  
As expected, HMVEC tube stability was impaired when incubated in growth medium 
supplemented with palmitate over the 24 hours following optimal tube formation 
(Supplemental Figure 1). Supplementation with low dose niacin (10 μM), vitamin D (10 
nM), and the combination of niacin (10 μM) and vitamin D (10 nM) significantly 
improved tube stability in high palmitate over the 24 h following tube formation (Figure 
3.1E). No significant differences were observed between niacin, vitamin D, and 
combination treatments on HMVEC tube formation or stability.  
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Figure 3.1. Niacin and vitamin D improve HMVEC tube formation and stability in 
high palmitate.  
(A) HMVEC were seeded onto growth factor replete Matrigel and incubated with media 
containing BSA (top row only) or 0.5 mM palmitate (PA) complexed to BSA (2:1 molar 
ratio). Resulting tube networks were visualized by light microscopy after 18, 24 and 42 h. 
Scale bar represents 100 μm. Cells were treated with vehicle (DMSO), niacin (NA), 
vitamin D (Vit D), or a combination of niacin plus vitamin D (NA + Vit D). For 
quantification, the entire well was assessed for total tube length using ImageJ software at 
each time point. (B) Cells were incubated with media containing BSA or PA media and 
treated with vehicle (DMSO), 10 μM niacin (NA), 10 nM Vitamin D (Vit D), a 
combination of 10 μM NA plus 10 nM Vit D for 18 hours. (C) Cells were incubated with 
media containing BSA or PA media and treated with vehicle (DMSO), 100 μM NA, 100 
nM Vit D and a combination of 100 μM NA plus 100 nM Vit D for 18 hours. (D) Cells 
incubated with 0.5 mM PA and treated with vehicle (DMSO), 10 μM niacin (NA), 10 nM 
Vitamin D (Vit D), a combination of 10 μM NA plus 10 nM Vit D were assessed for total 
tube length at 18, 24 and 42 h. (E) Areas under the curve were calculated from data in 
(D). Data are means±SEM for n=4. (B, C) * p<0.05 versus BSA. (D, E) * p<0.05 versus 
vehicle. 
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3.2 Niacin and vitamin D have distinct effects on HMVEC 
gene expression in high palmitate 
We took an unbiased approach of designing an Affymetrix GeneChip experiment to 
identify and compare genes and pathways that may underlie the improved endothelial cell 
formation observed in Matrigel assays. Using mRNA microarray analyses it was first 
confirmed that addition of palmitate to culture medium was representative of a lipotoxic 
environment by comparing the differential expression of genes between HMVEC treated 
with palmitate (0.5 mM) and BSA control following 16 hours of incubation. 
Unsurprisingly, palmitate induced expression of many genes involved in cell stress 
response, including ER stress (DDIT3, CXCL8), oxidative stress (HMOX1) and 
inflammation (IL1A), which is consistent with the known cellular responses to lipotoxic 
stress. Also consistent with lipotoxic conditions, the top 10 gene ontology (GO) 
categories and KEGG pathways for genes differentially expressed in response to high 
palmitate were related to cellular responses to stress (Table 3.1). Furthermore, treatment 
with palmitate did not alter the expression of niacin or vitamin D receptors, GPR109A 
and VDR, respectively.  
To compare gene expression changes that were common or specific to treatments, gene 
lists were created for niacin plus palmitate and vitamin D plus palmitate both compared 
to BSA control and summarized using Venny 2.1 (Oliveros, 2018) (Figure 3.2). 
Differentially expressed genes of interest specific to niacin plus palmitate treatment 
included increased expression of SMOX, a suggested antioxidant, decreased expression of 
BMX, an inflammatory marker, and decreased expression of MIR126. Genes 
differentially expressed specific to vitamin D plus palmitate treatment displayed 
increased expression of proposed modulators of inflammation (CEBPB and BAMBI).  
Interestingly, however, changes specific to vitamin D plus palmitate were predominantly 
related to cell cycle regulation, including decreased expression of CDK1 and MCM5. GO 
annotation and KEGG pathway analyses further confirmed the distinct effects of vitamin 
D on cell cycle-related genes and DNA repair signalling pathways (Table 3.2). Reactome 
pathway analyses were also consistent with pathway analyses from GO and KEGG. 
Reactome pathway analyses of differentially expressed genes in response to vitamin D 
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treatment identified robust overrepresentation of genes involved in pathways of cell cycle 
regulation, DNA replication, DNA repair, and signal transduction (Supplemental Figure 
3). 
To ensure that any observed changes in gene expression would not be due to the onset of 
cell death alone, the effects of vitamin D, niacin and palmitate on HMVEC cytotoxicity 
and viability were assessed before proceeding to RNA isolation. MTT assays showed that 
treatment of cells with BSA, palmitate, vitamin D or niacin or did not result in cellular 
cytotoxicity after 16 hours of incubation (Figure 3.3A). Percent viability calculated from 
trypan blue assays was not significantly different between treatment groups, with all 
treatments having viability greater than 80% (Figure 3.3B). These results suggest that 
vitamin supplementation or exposure to palmitate did not significantly affect HMVEC 
cytotoxicity or viability at 16 hours (Figure 3.3A,B). To further investigate results from 
the microarray bioinformatics suggesting that vitamin D was down regulating cell cycle 
gene expression, we performed a growth rate assay to determine the effect of niacin and 
vitamin D supplementation on HMVEC proliferation. Similar to our previous 
observations (Hughes-Large et al., 2014; Pang et al., 2016), niacin (10 μM) did not have 
an effect on HMVEC proliferation compared to control (Figure 3.3C). However, 
supplementation with vitamin D (10 nM) plus palmitate resulted in a significant decrease 
in population doublings compared to BSA control (Figure 3.3C). These results strongly 
suggest vitamin D supplementation is downregulating EC cycle under lipotoxic 
conditions.  
Transcript changes specific to niacin plus palmitate treatment revealed a highly 
significant and consistent 2-fold down regulation of MIR126 (Figure 3.2). This gene may 
be of interest to the effect of niacin on HMVEC tube formation and stability during 
lipotoxicity as it is one of the most abundant miRs in EC and is known to play a role in 
the regulation of EC angiogenesis both under basal conditions and in response to stress 
(Boon & Dimmeler, 2014). However, the microarray gene chip (Human Gene 2.1 ST) 
used for this study was not specific for pri/pre-miR-126 versus mature miR-126. 
Furthermore, pre-miR-126 gives rise to two mature strands, miR-126-3p and miR-126-
5p, which have been suggested to regulate EC angiogenesis under basal conditions and in 
response to stress, respectively (Boon & Dimmeler, 2014). Therefore, we examined if 
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there was a difference in expression of the three different forms of MIR126 between 
treatment groups following 8, 16 and 24 hours of incubation by qRT-PCR (Figure 3.4A-
C). In all three conditions, expression of pri/pre-miR-126 gradually decreased from 8 to 
24 hours, which is consistent with miR processing. Treatment with palmitate (0.5 mM) 
induced transient increases in expression of both miR-126-3p and miR-126-5p at 16 
hours, which returned to baseline expression by 24 hours (Figure 3.4A). In contrast, 
niacin treatment resulted in sustained 4- to 6-fold increases in both miR-126-3p and miR-
126-5p from 16 to 24 hours (Figure 3.4B). In contrast, vitamin D treatment resulted in 
highly variable expression of miR-126-3p and miR-126-5p over time (Figure 3.4C). 
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Table 3.1. Top 10 GO categories and KEGG pathways for genes differentially expressed 
in response to high palmitate.  
GO Category KEGG Pathway 
Response to stress TNF signaling pathway 
Response to chemical IL-17 signaling pathway 
Response to organic substance Cytokine-cytokine receptor inter. 
Cellular response to stimulus Pathways in cancer 
Response to stimulus NOD-like receptor signal. pathway 
Cellular response to stress NF-kappa B signaling pathway 
Response to O2 compound AGE-RAGE signal. (Diabetes) 
Response to ER stress Protein processing in ER 
ER unfolded protein response Ala, asp, and glut metabolism 
Cell response to chemical  ABC transporters 
Cells were incubated for 16 hours in growth medium supplemented with BSA or 0.5 mM 
palmitate (n=3). RNA was extracted and Affymetrix GeneChip microarray analyses were 
performed. Gene ontology (GO) categories and KEGG pathways were ranked according 
to enrichment p-values from the lists of differentially expressed genes (both up- and 
down-regulated) at > 2-fold (p < 0.05).  
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Figure 3.2. Comparison of gene expression changes in response to vitamin 
supplementation in the presence of high palmitate. 
Cells were incubated for 16 hours in growth medium supplemented with BSA, 0.5 mM 
palmitate (PA), 10 μM niacin, or 10 nM vitamin D (n=3). RNA was extracted and 
Affyetrix GeneChip microarray analyses were performed followed by generation of lists 
of genes differentially expressed at >2-fold, p<0.05, using Partek. Gene lists were 
summarized and compared to identify changes shared between treatments using Venny 
2.1. Numbers within each Venn diagram compartment represent the number of genes 
specific to or shared between indicated treatment(s). Selected gene changes were 
confirmed by qRT-PCR as indicated. First number in parentheses indicated relative 
change in gene expression determined by microarray analysis, and the second number 
indicates relative change determined by qRT-PCR. 
 
 
 
Palmitate +  
Vitamin D 
Palmitate + 
Niacin 
Palmitate 
SMOX (2.00, 3.75) 
BMX (-2.20, -1.78) 
MIR126 (-2.11, -1.96) 
BAMBI (2.37, 1.82) 
CEBPB (2.11, 4.18) 
CYP24A1 (2.17, 365.87) 
CDK1 (-2.13, -1.63) 
MCM5 (-2.05, -2.17) 
DDIT3 (7.74, 22.3)  
IL1A  (6.61, 10.3)  
HMOX1 (5.74, 9.88)  
CXCL8 (4.95, 7.49)  
MANF (Vit D:2.09, 2.98)  
             (NA: 2.03, 3.24) 
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Table 3.2. GO categories and KEGG pathways corresponding to changes in gene 
expression highlighted in Figure 3.2. 
GO Category KEGG Pathway  
Common to Palmitate, Palmitate + Niacin, and Palmitate + Vitamin D (101) 
Response to stress TNF signaling pathway 
Response to chemical IL-17 signaling pathway 
Response to organic substance Cytokine-cytokine receptor interaction 
Cellular response to stimulus Pathways in Cancer 
Response to stimulus NOD-like receptor signaling pathway 
Cellular response to stress NK-kappa B signaling pathway 
Response to O2 compound AGE-RAGE signaling 
Response to ER stress Protein processing in ER 
ER unfolded protein response Ala, asp, and glut metabolism 
Cell response to chemical  ABC transporters 
Specific to Palmitate + Vitamin D (62) 
DNA metabolic process Cell cycle 
DNA replication DNA replication 
Chromosomal part Homologous recombination 
Cell cycle process   
DNA repair   
Chromosome organization   
DNA replication initiation   
Regulation of cell cycle   
Specific to Palmitate + Niacin and Palmitate + Vitamin D (33) 
Cell response to DNA damage    
Cells were incubated for 16 hours in growth medium supplemented with 0.5 mM 
palmitate plus vehicle, 10 μM niacin, or 10 nM vitamin D. Gene ontology (GO) 
categories and KEGG pathways were ranked according to enrichment p-values from the 
comparative lists of differentially expressed genes (up- and down-regulated) at >2-fold, 
p<0.05. Numbers in brackets indicate the number of differentially expressed genes 
identified through Venn analyses as shared between treatment groups. 
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Figure 3.3. Vitamin D limits HMVEC population doubling without affecting cell 
viability in high palmitate.  
(A,B) Cells were incubated in media containing media containing BSA or 0.5 mM 
palmitic acid (PA) and treated with vehicle (DMSO), 10 μM niacin (NA), or 10 nM 
vitamin D (Vit D) for 16 h. (A) Absorbance was quantified spectrophometrically at a 
wavelength of 595 nm from standard MTT assays. (B) HMVEC viability was calculated 
from trypan blue assays. (C) Cells were plated at known, sub-confluent density and 
incubated in medium containing BSA or 0.5 mM palmitate (PA) with vehicle (DMSO), 
10 μM niacin, or 10 nM vitamin D (Vit D) for 16 hours. Cells were counted, and 
population doublings calculated. Data are means ± SEM for n=5, * p<0.05. 
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Figure 3.4. Niacin induces stable expression of miR126-5p and -3p in HMVEC 
exposed to high palmitate. 
(A-C) Cells were incubated for 8, 16, or 24 hours in medium supplemented with 0.5 mM 
palmitate and treat with vehicle (A), 10 μM niacin (B), or 10 nM Vit D (C). qRT-PCR was 
performed using primers for pri/pre-miR-126, miR-126-5p and miR-126-3p. Data are 
presented as fold changes normalized to baseline expression at 0 hours. Data are 
means±SEM for n=4, * p<0.05 for 24 hours compared to 8 hours. 
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3.3 Niacin, but not vitamin D, improves recovery of hind 
limb function following acute ischemic injury in obese 
mice with metabolic syndrome 
Lipotoxicity-induced EC dysfunction limits vascular repair and regeneration in vivo (Kim 
et al., 2012). In order to determine if the beneficial effects of niacin and vitamin D on 
angiogenic processes (Figure 3.1) could be translated to an in vivo model of obesity, 
hyperlipidemia, and PVD, we used western diet-fed 129S6 mice with surgically induced 
hind limb ischemia. Western diet feeding for a total of 17 weeks ad libitum induced 
characteristics of metabolic syndrome in all mice as indicated by increased adiposity, 
hyperlipidemia, and hepatic steatosis (Table 3.3) compared to observation of age-
matched lean control 129S6 mice fed a standard show diet (epididymal fat: 0.37 ± 0.04 g; 
plasma cholesterol: 2.85 ± 0.12 mmol/L; liver triglycerides: 13.3 ± 2.0 mg/g) (Pang et al., 
2016). However, the extent of metabolic impairment induced by Western diet feeding in 
this thesis was not as dramatic as in our previous work, as indicated by near-normal 
fasting blood glucose concentrations in all groups (Table 3.3). Interestingly, both vitamin 
D treatment groups had significantly lower levels of liver cholesterol mirrored by 
increased levels of plasma TG and cholesterol, suggesting that vitamin D 
supplementation resulted in metabolic disturbances with impaired lipid homeostasis 
(Table 3.3). In order to determine if treatment with either vitamin had an effect on 
parameters of cardiovascular health, heart rate or blood pressure were measured pre- and 
post-surgery.  Mean systolic blood pressure pre-surgery was 126 ± 3.8 mmHg with mean 
diastolic pressure of 84 ± 3.5 mmHg (Supplemental Figure 4A). Mean heart rate pre-
surgery was 716.5 bpm (Supplemental Figure 4B). Baseline systolic blood pressure of 
129S6 mice has previously been measured at 104 ± 3 mmHg using a tail-cuff 
computerized system (Salzler et al., 2007). There was no statistical difference in blood 
pressure or heart rate between treatment groups. Furthermore no statistical significance 
was found between pre- and post-surgery (Supplemental Figure 4C). 
On day 15 post-surgery, niacin-, but not vitamin D- or combination-treated mice had 
significant increases in mean hind limb contact time ratios (Figure 3.4A, B). Furthermore, 
over the two week treatment period only niacin-treated mice had a significant increase in 
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mean hind limb contact time ratios compared to vehicle-treated mice (Figure 3.4C). 
Similar to our previous observations in obese mice with hind limb ischemic injury (Pang 
et al., 2016), there were no significant differences found in mean hind limb contact 
intensity ratios between treatment groups (Figure 3.4D, E). 
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Table 3.3. Metabolic parameters of 129S6/SvEv mice. 
Treatment Vehicle Niacin Vitamin D 
Niacin + 
Vitamin D 
Initial body weight (g) 20.26 ± 1.04 21.04 ± 0.41 21.04 ± 0.56 20.40 ± 0.41 
Body weight at week 15 (g) 33.16 ± 2.24 34.60 ± 1.25 34.50 ± 1.65 33.88 ± 0.86 
Body weight at sacrifice (g) 28.95 ± 1.90 29.5 ± 0.74 27.96 ± 1.05 27.21 ± 1.61 
Food Intake (kcal/day)  9.02 ± 0.50 9.26 ± 0.45 8.58 ± 0.49 7.93 ± 1.01 
Epidydimal fat weight (g) 1.36 ± 0.19 1.18 ± 0.06 1.18 ± 0.13 1.10 ± 0.13 
Liver weight (g) 1.04 ± 0.07 1.02 ± 0.05 1.01 ± 0.06 1.02 ± 0.05 
Liver triglycerides (mg/g) 73.34 ± 9.24 69.04 ± 5.58 50.79 ± 9.32 33.84 ± 7.00* 
Liver cholesterol ester (mg/g) 8.11 ± 0.76 8.30 ± 1.12 4.56 ± 1.12* 2.47 ± 0.32* 
Liver free cholesterol (mg/g) 3.00 ± 0.09 2.88 ± 0.04 2.83 ± 0.05 2.76 ± 0.08 
Plasma ALT (U/L) 20.14 ± 2.13 20.00 ± 2.13 21.83 ± 2.92 30.33 ± 10.99 
Plasma AST (U/L) 92.86 ± 25.61 80.83 ± 11.33 73.50 ± 15.88 130.5 ± 18.58 
Plasma triglycerides (mmol/L) 0.63 ± 0.04 0.66 ± 0.03 0.95 ± 0.05* 0.78 ± 0.07 
Plasma free fatty acids (mmol/L) 0.43 ± 0.05 0.57 ± 0.04 0.59 ± 0.06 0.40 ± 0.03 
Plasma cholesterol (mmol/L) 4.28 ± 0.10 3.86 ± 0.16 5.04 ± 0.19* 3.69 ± 0.25 
Blood glucose (mmol/L) 5.24 ± 0.32 4.24 ± 0.31 5.19 ± 0.39 4.77 ± 0.39 
Insulin (ng/ml) 0.35 ± 0.05 0.40 ± 0.07 0.36 ± 0.04 0.22 ± 0.02 
 
Five week old male 129S6 mice were maintained on a western diet (42% calories from 
fat) for 17 weeks. Following 15 weeks of feeding, mice underwent unilateral femoral 
artery ligation and excision surgery. Following surgery, mice received once daily i.p. 
injections of vehicle (DMSO), niacin (50 mg/kg), vitamin D (200 ng/kg), or niacin and 
vitamin D (50 mg/kg and 200 ng/kg, respectively) for 14 days. Food intake was measured 
post-surgery. Body weight and blood glucose measurements were performed immediately 
prior to sacrifice (day 15). All remaining parameters were determined as indicated, or 
post-mortem. Data are means±SEM. * p<0.05 versus vehicle, n=7-8. 
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Figure 3.5. Niacin improves recovery of hind limb function after hind limb ischemic 
injury in obese mice with metabolic syndrome.  
Five week old male mice were maintained on a western diet for 15 weeks, followed by 
unilateral femoral artery ligation and excision surgery. Following surgery, mice received 
once daily i.p injections of vehicle, niacin (50 mg/kg), vitamin D (200 ng/kg), or niacin 
plus vitamin D (50 mg/kg and 200 ng/kg, respectively) for 14 days. (A) On days 3, 9 and 
15 post-surgery, gait analyses were performed using a Catwalk system. Representative 
contact duration maps are shown for day 15. Black arrows indicate the injured limb. (B) 
Mean hind limb contact times and (D) mean hind limb contact intensities were used 
calculate hind limb use ratios for each day. A ratio of <1.0 indicates decreased use of the 
injured limb. (C, E) Areas under the curve for paw contact times and intensities over the 
course of treatment were calculated from data in (B, D, respectively). Data are 
means±SEM for n = 8. * p<0.05 versus vehicle.  
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3.4 Vitamin D does not promote vascular or myofiber 
regeneration of tibialis anterior muscles in diet-induced 
obese mice with metabolic syndrome 
The tibialis anterior muscle undergoes significant necrosis and inflammation with 
subsequent vascular and muscular regeneration in response to femoral artery ligation and 
excision surgery (Arpino et al., 2017). To determine if recovery of hind limb function 
was associated with corresponding tissue revascularization and myofiber regeneration, 
vessel densities, arteriole diameters and muscle architecture were quantified. There were 
no significant differences between treatment groups for capillary and arteriole densities 
per myofiber area across the length of the tibialis anterior muscle, as determined by 
staining for CD31+ and αSMA+, respectively (Figure 3.6A-C). Furthermore, there were 
no significant differences in arteriole diameter observed between treatment groups 
(Figure 3.6D). These results are consistent with previous findings from our lab, published 
by Pang et al. (2016), which showed similar results in arteriole and capillary density data 
with niacin treatment compared to control. 
Quantification of tibialis anterior muscle architecture revealed no significant differences 
in percentages of regenerating (central nuclei), non-regenerating (peripheral nuclei), and 
necrotic (no visible nuclei) myofibers (Figure 3.7A, B). However, the proportions of 
regenerating to non-regenerating myofibers were markedly lower in mice treated with 
vitamin D, either alone or in combination with niacin (Figure 3.7C). These results may 
suggest that proportions of regenerating to non-regenerating myofibers may partially 
account for functional differences observed between treatment groups. Since 
accumulation of interstitial adipose tissue is associated with persistent muscle damage 
and can impair muscle function (Sciorati et al., 2015), adipose tissue areas were measure 
in hematoxylin and eosin stained sections. There were no significant differences in 
adipose tissue area between treatment groups (Figure 3.7D). 
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Figure 3.6. Effect of niacin and vitamin D on vascular regeneration in diet-induced 
obese mice with hind limb ischemia.  
(A) Sections were immunostained for CD31 (brown, black arrowhead), to identify 
endothelial cells, and smooth muscle α-actin (αSMA) (red, white arrowhead), to identify 
vascular smooth muscle cells. Scale bar = 100 µm. (B, C) Capillary and arteriole 
densities were determined by counting CD31+ vessels and αSMA+ vessels, respectively. 
Vessel densities were normalized to myofiber areas per section. Data are means±SEM for 
n = 7-8. (D) To generate arteriole diameter frequency plots for each treatment, arteriole 
diameters for all vessels in all muscle sections were determined. Values in parentheses 
indicate mean vessel diameters±SEM for each treatment group. 
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Figure 3.7. Vitamin D does not promote myofiber regeneration in tibialis anterior 
muscles following acute ischemic injury in diet-induced obese mice 
(A) Sections were stained with hematoxylin and eosin and regenerating myofibers were 
identified by intense eosin staining and central nuclei (white arrowhead), non-
regenerating myofibers were identified by intense eosin staining and the presence of 
peripheral nuclei (black arrowhead), and necrotic myofibers were identified by pale eosin 
staining and absent nuclei. Scale bar = 100 µm. (B) Myofiber areas were determined, and 
percentages of each myofiber type (regenerating, non-regenerating, or necrotic) were 
calculated for each section. (C) Ratio of regenerating to non-regenerating myofibers were 
calculated for each section. (D) Adipose tissue areas were determined and calculated as 
percentages of total section area. Data are means±SEM for n=7-8. * p<0.05 versus 
vehicle.  
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3.5 Vitamin D does not decrease inflammation or fibrosis of 
tibilas anterior muscles in diet-induced obese mice with 
metabolic syndrome 
Sustained inflammation and increased interstitial fibrosis are associated with impaired 
myofiber regeneration (Sciorati et al., 2015). Therefore, macrophage content and 
collagen deposition were quantified. Furthermore, a fibrosis location score was quantified 
for each mouse, where a higher score indicates increased presence of myofiber-associated 
collagen. Collagen associated with myofibers has a greater negative impact on muscle 
function than adipose-associated collagen. Treatment with vitamin D, either alone or in 
combination with niacin did not decrease inflammation or fibrosis (Figure 3.8A-C) and 
did not significantly impact the location of collagen deposition (fibrosis location score) 
(Figure 3.8E). Interestingly, mice treated with niacin alone exhibited consistent, though 
not statistically significant, decreases in inflammation and fibrosis (Figure 3.8C-E).  
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Figure 3.8. Vitamin D does not improve inflammation or fibrosis in tibialis anterior 
muscles following acute ischemic injury in diet-induced obese mice.  
(A) Sections were immunostained for F4/80 (brown, white arrowhead) to identify 
macrophages. (B) Sections were stained with Masson’s trichrome to identify collagen 
fibrosis (light blue, black and grey arrowheads). Scale bars = 100 μm. (C, D) 
Macrophage and collagen areas were quantified and expressed as percentages of total 
section areas. (E) Fibrosis location score was determined for each mouse. A higher score 
indicates greater presence of myofiber-associated collagen (black arrowhead). Data are 
means±SEM for n=7-8. 
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Chapter 4  
4 Discussion 
4.1 Summary of Results 
Endothelial dysfunction, in the setting of lipotoxicity during obesity and metabolic 
syndrome, has been identified as a surrogate marker for the development of vascular 
complications, including the commonly associated, but often underdiagnosed condition 
of PVD (Campia et al., 2012). Current therapies for PVD are limited and fail to target 
endogenous revascularization of the ischemic tissue. Furthermore, current intervention 
strategies have shown limited success in Canada’s Indigenous population that carries a 
disproportionate burden of obesity-related diseases. Therefore, it is important to develop 
better understanding of therapeutic agents that may be useful interventions against 
endothelial dysfunction during obesity and metabolic syndrome.  Observational studies 
have suggested an association between low circulating levels of vitamin D and increased 
PVD risk in human populations (Gouveri et al., 2012; Nsengiyumva et al., 2015), 
offering the notion that increased vitamin D supplementation either through 
pharmacological doses, or increased dietary intake, may provide vascular benefit.  
Current knowledge of the effects of vitamin D supplementation for prevention of CVD 
are conflicting with no data yet available from large randomized, placebo-controlled 
vitamin D primary prevention or intervention trials. Furthermore, the effects of vitamin D 
on peripheral ischemia and vascular regeneration in the setting of obesity and metabolic 
syndrome are lacking and may be context dependent. Additionally, combined 
supplementation with other vitamins associated with improved endothelial cell function, 
such as niacin, may offer additive or synergist effects. Recent work from our lab has 
shown that low dose niacin promotes HMVEC tube formation as well as enhances vessel 
smooth muscle investment and improves functional recovery and tissue architecture of 
tibialis anterior muscles in diet-induced obese mice following ischemic injury (Hughes-
Large et al., 2014; Pang et al., 2016). Therefore, it was hypothesized that 
supplementation of vitamin D alone and in combination with niacin, would improve EC 
angiogenic function and promote vascular regeneration under lipotoxic conditions that 
occur during obesity and metabolic syndrome.  
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Figure 4.1 summarizes the major findings of this thesis, which are as follows: 1) Both 
niacin and vitamin D improved HMVEC tube formation and stability in high palmitate. 
2) Niacin and vitamin D increased stress response and anti-inflammatory gene expression 
in response to high palmitate. However, vitamin D decreased cell cycle gene expression, 
which was associated with reduced HMVEC population doubling, while niacin induced 
stable expression of miR126-3p and -5p. 3) Niacin, but not vitamin D or the combination, 
improved recovery of hind-limb function following ischemic injury in obese mice with 
metabolic syndrome. 4) Recovery of hind limb function was achieved despite no 
improvements in revascularization, regeneration, inflammation and fibrosis of the tibialis 
anterior muscle of niacin-treated mice. However, treatment with vitamin D, either alone 
or in combination with niacin, significantly impaired myofiber regeneration. 
4.2 Niacin and Vitamin D Improves Endothelial Cell 
Angiogenic Function in High Palmitate 
There is compelling evidence linking vitamin D and cardiovascular function, raising the 
intriguing possibility that a causal relationship exists between vitamin D deficiency and 
CVD progression. In support of this concept, Wong et al. (2014) showed improved 
vascular regeneration in lean, diabetic rodent models of vascular injury. Furthermore, 
several clinical studies have demonstrated improvements in endothelial function 
following vitamin D supplementation, in patients with T2DM (Sugden et al., 2008; 
Hussin et al., 2017), in healthy patients with vitamin D deficiency (Tarcin et al., 2009) 
and in patients at risk for CVD development (Reynolds et al., 2016). However, the effects 
of vitamin D on EC function and vascular regeneration under lipotoxic conditions are 
lacking. Thus, it was determined whether vitamin D would have similar benefits on 
endothelial function in a high fat setting that would be typical during obesity and 
metabolic syndrome. Furthermore, the effects of combined supplementation with niacin, 
were determined to identify any potential additive or synergistic effects.  
In vitro data showed that low dose supplementation of vitamin D alone and in 
combination with niacin, improved EC tube formation in high palmitate. These data are 
consistent with an earlier study showing increased tube formation with vitamin D during  
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Figure 4.1. Summary of vitamin D and niacin supplementation on EC function and 
vascular regeneration during lipotoxicity. 
Both niacin and vitamin D improved endothelial tube formation and stability in high 
palmitate. However, only niacin improved functional recovery in obese mice following 
ischemic injury. Treatment with vitamin D, either alone or in combination with niacin, 
significantly impaired myofiber regeneration with no improvements observed in hind-
limb function, revascularization, inflammation or fibrosis. Both niacin and vitamin D 
increased stress response and anti-inflammatory gene expression in EC exposed to high 
palmitate. However, vitamin D decreased cell cycle gene expression, which was 
associated with suppression of EC proliferation, which may have limited vascular 
regeneration and recovery of limb function in vivo. Furthermore, vitamin D-treated mice 
exhibited metabolic disturbances and impaired lipid homeostasis, which may affect 
processes of vascular regeneration. Niacin-treated mice exhibited consistent, though not 
statistically significant, decreases in inflammation and fibrosis of the tibialis anterior 
muscle. Niacin induced relatively stable expression of miR-126-3p and miR-126-5p, 
which may have contributed to improved EC function in vitro. 
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exposure to preeclampsia-related inflammatory factors (Brodowski et al., 2014). 
Furthermore, consistent with our previous results (Hughes-Large et al., 2014; Pang et al., 
2016), low dose niacin supplementation improved HMVEC tube formation upon 
exposure to palmitate. In addition to improved EC tube formation, low dose 
supplementation of vitamin D alone and in combination with niacin, also promoted 
HMVEC tube network stabilization in high palmitate. This observation is consistent with 
earlier studies, showing that niacin plays a key role in increasing the longevity of 
endothelial tube networks in an NAD
+
-dependent manner, under the stress inducing 
condition of high glucose (Borradaile & Pickering, 2009b). Vitamin D has also been 
shown to promote EC longevity, by protecting EC from oxidative stress and promotion of 
cell survival pathways (Uberti et al., 2014). Promotion of EC survival and longevity are 
important considerations for revascularization following vascular injury. Functional 
revascularization requires newly formed microvasculature networks to survive long 
enough to recruit smooth muscle cells and arteriogenesis initiation (van der Veer et al., 
2005; Borradaile & Pickering, 2009b). Interestingly, no additional benefit on tube 
formation or stability was observed with the combination treatment, suggesting no 
additive or synergistic effect of using the combination treatment on HMVEC function in 
vitro.  
4.3 Modulation of Endothelial Cell Gene Expression by 
Niacin and Vitamin D  
High levels of circulating fatty acids during obesity and metabolic syndrome are well 
known risk factors for the development of CVD (Mathew et al., 2010).  Saturated fatty 
acids, in particular, are known to play an important role in mediating endothelial 
dysfunction (Kim et al., 2005; Liu et al., 2012). Palmitate, the most abundant dietary 
saturated fatty acid, has been shown to induce oxidative stress, ER stress, and 
inflammatory pathways in endothelial cells (Battson et al., 2017; Ghosh et al., 2017). The 
global gene expression data provided in this thesis clearly support this earlier work 
(Table 3.1). Treatment with vitamin D in high palmitate resulted in decreased expression 
of CEBPB and BMABI, which are proposed modulators of inflammation; whereas 
treatment with niacin resulted in increased expression of SMOX, a suggested antioxidant, 
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and decreased expression of BMX, an inflammatory marker. These results are consistent 
with previous findings that niacin and vitamin D are both able to suppress EC mediators 
of inflammation and oxidative stress in response to inflammatory stimuli (Digby et al., 
2012b; Dalan et al., 2014). However, neither vitamin was able to completely suppress 
stress response and inflammatory pathways during high palmitate in vitro (Figure 3.2). 
This in vitro model only tested the effect of niacin and vitamin D on one vascular cell 
type, which may account for the lack of complete stress response and inflammatory 
suppression as indicated by global gene expression. Both niacin and vitamin D treatment 
have been shown to have anti-inflammatory effects on various cell types including 
adipocytes (Digby et al., 2010; Cimini et al., 2017), as well as macrophages and 
neutrophils (Lipszyc et al., 2013; Digby et al, 2012a; Bellan et al., 2018), to limit the 
contribution of systemic inflammation to perivascular inflammation and stress (Berg & 
Scherer, 2005; Libby et al., 2009).  
Although vitamin D was able to improve EC angiogenic function as measured by tube 
formation and stability in high palmitate, microarray data revealed that vitamin D 
decreased the expression of several cell cycle genes, which was associated with 
suppression of cell proliferation. Vitamin D exerts its effects predominantly through 
activation of its receptor, VDR, and has been reported to have effects on cell cycling, 
proliferation, and apoptosis in a wide variety of cell types (Holick, 2007). Consistent with 
our findings, vitamin D has been shown to elicit anti-proliferative effect on EC in the 
setting of tumor progression and in malignant cell types (Majewski et al., 1993; Saghiri et 
al., 2017; Jamali et al., 2018). Furthermore, it has been shown that vitamin D can 
suppress proliferation of other vascular cell types including cardiomyocytes and VSMC 
by promoting cell cycle arrest in G1/G0 phase  (Wu-Wong et al., 2006; Artaza et al., 
2010). Despite downregulation of cell cycle genes and suppressed proliferation, this did 
not impact in vitro angiogenic function as measured by Matrigel assays. This assay relies 
predominantly on endothelial cell migration rather than proliferation, and thus the 
beneficial effects of vitamin D on anti-inflammatory gene expression, were likely able to 
contribute to improved tube formation and stability in vitro. 
MicroRNAs (miRs) are small noncoding RNAs that modulate gene expression post-
transcriptionally (Bartel, 2004). Several miRNAs have been shown play important roles 
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in the regulation and control of vascular function, contributing to both vascular 
homeostasis and disease (Latronico et al., 2007; Feinberg & Moore, 2016). Microarray 
analyses identified miR126 to be differentially expressed in response to niacin treatment 
in high palmitate. Further investigation of miR126 regulation through qRT-PCR analyses 
revealed that niacin may induce relatively stable expression of both miR126-3p and 
miR126-5p. MiR-126 has been identified as a regulator of angiogenesis and plays a 
critical role in vascular development (Wang et al., 2008a; Chistiakov et al., 2016). The 
precursor, pre-miR-126, gives rise to two mature strands, miR-126-3p and miR126-5p, 
both of which are biologically active (Fish et al., 2009; Weber et al., 2014). Similar to 
our findings, one study has shown that treatment with niacin upregulated miR-126 in 
retinal EC under the stress inducing condition of high glucose (Wang & Yan, 2016). 
miR126-3p and miR126-5p have been implicated in the promotion of an anti-
inflammatory state, and of proliferation in response to EC stress, respectively (Boon & 
Dimmeler, 2014; Feinberg & Moore, 2016). Schober et al. (2014) found that expression 
of miR-126-5p was essential to EC proliferation during hyperlipidemia and resulted in 
reduced atherosclerotic lesions. These findings suggest that therapeutic agents promoting 
miR-126-5p expression in EC could have atheroprotective potential (Schober et al., 
2014). Since miR-126 is known to play a key role in the regulation of EC angiogenic 
function, it is possible that niacin-mediated expression of miR-126 may be one 
mechanism by which niacin improved EC tube formation and stability under lipotoxic 
conditions in Matrigel assays.  
4.4 Vitamin D does not Improve Functional Recovery in 
Obese Mice with Acute Ischemic Injury  
Although observational studies have suggested an inverse relationship between vitamin D 
intake and PVD risk in human populations, there are no data yet available from large 
randomized, placebo-controlled vitamin D primary prevention or intervention trials. 
There is convincing evidence to support the relationship between vitamin D 
supplementation and improved vascular function in vitro; however, the translation of this 
relationship in vivo is often conflicting or inconclusive (Bellan & Marzullo, 2018). Data 
presented in this thesis show that although vitamin D supplementation was able to 
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improve in vitro angiogenic function of EC under lipotoxic conditions, intervention did 
not improve recovery of hind limb function in obese mice following acute hind limb 
ischemic injury. This finding raises questions as to whether vitamin D supplementation 
may be beneficial under established lipotoxic environments in vivo.  
Recent reports indicate that vitamin D supplementation can promote vascular 
regeneration in lean, diabetic rodent models of vascular injury (Wong et al., 2014; 
Leisegang et al., 2016). However, equally compelling work clearly showed that treatment 
with vitamin D limited neovascularization and promoted anti-angiogenic effects on tumor 
derived EC (Majewski et al., 1993; Mantell et al., 2000), and on retinal EC (Albert et al., 
2007). It is possible that the timing of vitamin D administration determines its therapeutic 
effect on vascular regeneration. For studies of vascular regeneration, vitamin D was 
administered prior to vascular injury; while for studies of tumour progression, vitamin D 
administration was either concurrent with or after the initial establishment of tumours. 
The latter intervention protocol is most similar to the protocol we used, is relevant to the 
human treatment scenario, and could partly account for the lack of benefit of vitamin D 
that we observed. This general concept is consistent with negative data from the EVITA 
trial of vitamin D supplementation in heart failure patients (Zittermann et al., 2017), and 
with preliminary analyses from VITAL showing fewer advanced cancer diagnoses among 
patients receiving vitamin D (Manson et al., 2019).  
Multiple observations have been reported that suggest a relationship between abnormal 
serum vitamin D levels and dysregulation of vitamin D metabolism during obesity 
(Earthman et al., 2012; Ding et al., 2012; Clemente-Postigo et al., 2015). The lack of 
effect on hind limb revascularization and recovery of limb function could be related to 
increased adiposity of the diet-induced mouse model. Evidence suggests that increased 
adiposity in an obese individual acts as a reservoir for vitamin D, reducing serum vitamin 
D concentration, which may account for conflicting results from trials evaluating vitamin 
D supplementation on endothelial function (Drincic et al., 2012; Carrelli et al., 2017). For 
example, Carrara et al., (2014) found that vitamin D improved endothelial function, as 
measured by FMD following treatment with vitamin D. However, a recent finding from 
Borgi et al., (2017) that used similar dosing and endpoint evaluations, did not find a 
benefit of vitamin D on endothelial function. The latter trial included overweight and 
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obese subjects, raising the intriguing possibility that in the setting of obesity, vitamin D 
may not be a useful intervention to protect against endothelial dysfunction. In further 
support of this concept, Lee et al. (2018) showed that vitamin D supplementation was 
able to modulate innate immunity in lean mice, but this effect was absent in diet-induced 
obese mice. 
Not only can obesity and increased adiposity disrupt the effectiveness of vitamin D, but 
emerging evidence suggests that vitamin D may play a role in regulating energy 
metabolism and lipid levels. However, the effect of vitamin D supplementation on lipid 
and lipoprotein metabolism is highly controversial and unclear (Challoumas, 2014; 
Schwetz et al., 2018). Results from this thesis suggested that Vitamin D may have 
disrupted lipid homeostasis, as observed by decreased liver lipids and corresponding 
increases in plasma TG and cholesterol (Table 3.3). A recent trial found that vitamin D 
supplementation resulted in unfavorable effects on lipid and lipoprotein metabolism, 
noted by increased serum lipids including total cholesterol and serum TG (Schwetz et al., 
2018). These results are consistent with previous randomized control trials noting an 
unfavourable effect of vitamin D on lipid levels (Maki et al., 2011; Pilz et al., 2015). 
Conversely, observational studies have shown that patients with higher serum vitamin D 
concentrations displayed favourable lipid profiles compared to vitamin D deficient 
patients (Ponda et al., 2012; Chaudhuri et al., 2013; Kelishadi et al., 2014). In addition, 
several intervention studies have also shown neutral effects of vitamin D supplementation 
on lipid metabolism (Nagpal et al., 2009; Jorde et al., 2010; Witham et al., 2013). 
Consistent with our results, several studies using diet-induced obese mice have shown an 
increase in hepatic fatty acid oxidation with corresponding decreases in hepatic lipid 
accumulation following vitamin D supplementation (Yin et al., 2012; Marcotorchino et 
al., 2014; El-Sherbiny et al., 2018). Unfavorable lipid profiles are known contributors to 
EC lipotoxicity, disrupted EC function and limited vascular regeneration (Campia et al., 
2012; Kim et al., 2012). Despite controversial evidence for the effect of vitamin D on 
serum lipids, it is possible that the changes in lipid metabolism associated with vitamin D 
intervention in our model, may have limited vascular regeneration, repair and functional 
recovery in vivo.  
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The lack of effect on hind limb revascularization and recovery of limb function could 
also be related to the inhibition of cell cycle gene expression observed in cultured EC 
exposed to vitamin D in the presence of high palmitate. Although vitamin D 
supplementation resulted in improved in vitro angiogenic function, it is entirely possible 
that impaired endothelial cell proliferation, in the setting of pre-existing tissue damage 
induced by femoral artery ligation and excision, limited vascular regeneration in vivo.  
This is consistent with the anti-angiogenic effects of vitamin D previously observed in 
various experimental models. Albert et al. (2007) showed that vitamin D inhibited retinal 
neovascularization via suppression of EC proliferation. Numerous studies have outlined 
the anti-angiogenic effect of vitamin D on tumor vascularization  (Mantell et al., 2000; 
Maj et al., 2016; Jamali et al., 2018). Lastly, vitamin D has also been shown to inhibit 
angiogenesis in a rodent model of endometriosis by reducing angiogenic factors and 
inhibiting ECM degradation (Yildirim et al., 2014). 
Vascular regeneration is a complex process, not only requiring proliferation and 
migration of EC, but also the co-ordination and recruitment of several other vascular cells 
types, and their assembly into new, functional vessels (Shirali et al., 2018). The 
angiogenic effects of vitamin D may depend on vascular cell type. Although vitamin D 
has been shown to elicit pro-angiogenic effects on vascular EC in lean rodent models of 
vascular injury, it has been show to inhibit VSMC proliferation and migration (Raymond 
et al., 2005). VSMC are required for vascular integrity and function and are a major 
cellular component involved in vascular regeneration (Greenberg et al., 2008). It is 
possible that vascular regeneration and functional recovery were limited in vivo due to 
different effects of vitamin D on the various vascular cell types involved the vascular 
regenerative process.  
4.5 Combined Vitamin Supplementation and Functional 
Recovery in Obese Mice with Acute Ischemic Injury 
Previous work from our lab has shown that treatment with niacin improved recovery of 
hind limb function in the same mouse model (Pang et al., 2016). Data presented in this 
thesis confirmed the effect of niacin on functional recovery, which corresponded with 
consistent, although not statistically significant, beneficial effect on tibialis anterior 
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macrophage content (-56%, p=0.065) and fibrosis (-24%, p=0.060). These findings 
support previous work showing that niacin, through modulation of immune cell activity, 
promoted vascular function and repair (Ganji et al., 2009; Lukasova et al., 2011; Digby et 
al., 2012a; Wu et al., 2012).  Interestingly, however, improvement in functional recovery 
and the associated modest effect at the tissue level were not evident in mice treated with 
vitamin D alone or in combination with niacin, providing evidence that intervention with 
vitamin D was sufficient to abrogate the beneficial effects of niacin.  
Both niacin and vitamin promote normal EC function through similar mechanisms as 
shown in Figure 1.2, including increased NO production via increased eNOS activation, 
decreased ROS production and decreased production of inflammatory molecules (Digby 
et al., 2012b; Dalan et al., 2014). The lack of beneficial effect with the combination 
treatment in vivo and absence of additive or synergistic effects with the combination in 
vitro could partly be related to saturation of these pathways. The enzymatic activity of 
NOS is tightly regulated and largely dependent on cofactor availability as well as 
arginine and oxygen availability. Changes in concentration or availability to any of these 
major substrates can result in profound influences on NOS activity and thus NO 
signalling (Thomas et al., 2008). It is possible that combining niacin and vitamin D 
offered no additional increase in NOS activity and NO-mediated signalling in EC if their 
downstream targets converged on the similar pathways. Furthermore, it is possible that 
the combination of niacin and vitamin D did not offer an additive or synergistic 
interaction with respect to total antioxidant capacity as it is possible that signalling 
pathways related to increased antioxidant potential may have been saturated by either 
vitamin alone.   
In addition, the absence of beneficial effects of niacin in the combination treatment could 
be partly related to the distinct effects of these vitamins on gene expression in EC. In 
contrast to vitamin D, niacin did not decrease expression of cell cycle regulators (Table 
3.2) and did not inhibit EC population doublings (Figure 3.3C). Furthermore, niacin 
induced relatively stable expression of miR126-3p and -5p, which have been implicated 
in regulation of EC functions; it is possible that these distinct and opposing effects on EC 
function may account for the lack of functional recovery and revascularization in vivo 
with the combination treatment.  
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These observations of co-supplementation of only two vitamins in a tightly controlled 
experimental system raise questions as to the effectiveness of multivitamin supplements 
for CVD benefit. It is possible that constituents of multi-vitamins may have opposing 
effects on gene expression related to vascular process in the humans and may account for 
the lack of CVD benefit observed in recent meta-analyses (Jenkins et al., 2018). 
Furthermore, this outlines the importance of studying the potential risk of interactions 
between vitamins and micronutrients to elucidate the advantages and disadvantages of 
different combination for the promotion of health.  
4.6 Limitations and Future Directions 
Our in vitro model of EC tube formation and stability only tested the effect of niacin and 
vitamin D on one vascular cell type. Vascular regeneration is a complex process, not only 
requiring proliferation and migration of EC, but also the co-ordination and recruitment of 
several other vascular cells types, such as VSCM, which are required for vascular 
integrity and function and are a major cellular component involved in vascular 
regeneration (Shirali et al., 2018). Vitamin D has been show to inhibit VSMC 
proliferation and migration (Raymond et al., 2005. It would be interesting to expand the 
findings from this thesis to other vascular cell types, especially since vitamin D has been 
show to inhibit VSMC proliferation and migration (Raymond et al., 2005). One focus 
would be to co-culture EC with VSMC in Matrigel assays of tube formation and stability. 
Co-culturing with VSMC, or other cell types such as pericytes, may provide insight into 
differences between findings in vitro of improved EC tube formation and stability with 
vitamin D supplementation, and findings in vivo of impaired myofiber regeneration and 
lack of function recovery following vitamin D intervention. 
We previously showed that niacin enhanced recovery of hind limb function in the same 
mouse model  (Pang et al., 2016).  Here, we confirmed the effect of niacin on recovery of 
limb function, and found that this was associated with consistent, though statistically non-
significant, reductions in tibialis anterior macrophage content (-56%, p=0.065) and 
fibrosis (-24%, p=0.060). These beneficial effects of niacin were less dramatic than 
observed as in our earlier work (Pang et al., 2016), most likely because induction of 
metabolic disease was less pronounced in the current study, as indicated by near normal 
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fasting blood glucose concentrations in all groups (Table 3.3).  This resulted in greater 
recovery of limb function in the vehicle-treated group in the study presented in this 
thesis. Nonetheless, these data generally support previous work in lean rodent models 
showing that niacin can promote vascular function and repair by modulating the activity 
of immune cells (Ganji et al., 2009; Lukasova et al., 2011b; Tavintharan et al., 2011; 
Digby et al., 2012a; Wu et al., 2012). 
The unexpected negative effects of vitamin D on vascular regeneration in an obese mouse 
model presented in this thesis highlights the need for further research to identify potential 
TCAM therapies that may be useful intervention and/or prevention strategies for CVD 
risk. Currently available pharmacotherapies for PVD are limited and generally focus on 
symptom relief for thrombosis and claudication pain management rather than promoting 
endogenous revascularization of the ischemic tissues (Farber & Eberhardt, 2016). It 
would be interesting to expand this project to investigate other naturally occurring, diet-
derived compounds that may be useful TCAM interventions for endothelial dysfunction 
resulting from lipotoxic environments seen in patients with obesity, metabolic syndrome 
and T2DM. The naturally occurring modified amino acid, ergothioneine is a suggested 
powerful antioxidant. Ergothioneine is mainly acquired through fungi dietary sources, 
and thus like niacin and vitamin D, is enriched in commonly consumed edible 
mushrooms. Ergothioneine is absorbed through the specific transporter organic cation 
transporter novel, type 1 (OCTN1) expressed in all human tissues (Gründemann et al., 
2005). Recent studies indicate that ergothioneine can accumulate in injured tissues, and it 
has been hypothesized that it acts through a protective or adaptive mechanism of action to 
minimize oxidative damage (Halliwell et al., 2018). However, there is limited knowledge 
of the effects of ergothioneine on EC angiogenic function under lipotoxic conditions. 
Future studies could be performed to determine the effects of ergothioneine 
supplementation, possibly with and without co-supplementation with niacin, on EC 
function and vascular regeneration under lipotoxic conditions to determine its potential 
use as a therapeutic agent for PVD.  
Beyond assessing MIR126 expression, the in vitro and in vivo findings in this thesis did 
not thoroughly investigate signaling pathways that may be involved in improved EC 
function and improvement in hind limb functional recovery observed with niacin 
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treatment. Previous findings from our lab have shown that the pro-angiogenic effect of 
niacin on EC is mediated by GPR109A (Hughes-Large et al,. 2014; Pang et al., 2016). 
One downstream signaling pathway of niacin-mediated GPR109A activation that may be 
particularly relevant to vascular regeneration is prostaglandin receptor activation, 
specifically prostaglandin D2 receptor (DP1) activation. Production of PGD2 is known to 
be mediated by GPR109A activation and is responsible for the adverse, yet relatively 
harmless, skin flushing experienced with niacin supplementation (Kamanna et al., 2009). 
GPR109A/PGD2/DP1 axis may be relevant to vascular regenerative properties of niacin 
supplementation as prostaglandins are known to have vasodilatory and cytoprotective 
effects (Suzuki et al., 2016). PGD2 has been shown to improve the barrier function of EC 
(Murata et al., 2008; Kobayashi et al., 2013), and a recent study demonstrated that DP1 
activation appears to be required for the myocardial protective effects of niacin (Kong et 
al., 2017). Future in vitro and in vivo studies using selective activators and/or inhibitors 
of the GPR109A/PGD2/DP1 axis will provide insight into whether the effects of niacin 
are mediated through this axis. It would also be useful to determine if niacin promotes EC 
functions through GPR109A activation independent of PGD2 activation of DP1. In order 
to determine if either receptor alone or in combination is required for the effects of 
niacin, cells could be transfected with either control siRNA or silencer select siRNA 
against either receptor. 
4.7 Relevance and Conclusions 
Maintenance of EC function can help reverse or attenuate vascular disease. Therefore, it 
is important to develop better understanding of therapeutic agents that may be useful 
interventions against endothelial dysfunction. Future PVD intervention and prevention 
strategies could target endogenous revascularization to improve CVD disease morbidity. 
Niacin and vitamin D are considered promising natural, therapeutic compounds as they 
are known to promote normal endothelial function. Results presented here raise questions 
as to the effectiveness of vitamin D supplementation to promote vascular regeneration 
under lipotoxic conditions that would be seen during obesity and metabolic syndrome.   
Another important finding of this thesis was that the beneficial effects of niacin were 
absent when co-supplemented with vitamin D. This underscores the importance of 
71 
 
 
understanding interactions between different therapeutic agents, especially TCAMs, and 
their effects on disease states. Ultimately, better understanding of the effects and 
mechanisms of action of TCAM therapies on the vasculature will help to guide 
therapeutic as well as nutritional recommendations for obese patients with PVD.  
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Appendix C: Supplemental Information 
 
Supplemental Figure 1. HMVEC tube stability was impaired in high palmitate.   
(A) Cells were seeded onto growth factor replete Matrigel and incubated with media 
containing BSA or 0.5 mM palmitate (PA) complexed to BSA. Cells were treated with 
vehicle (DMSO). Resulting tube networks were imaged at 18, 24 and 42 hours by light 
microscopy. (B) The entire well was assessed for total tube length using ImageJ software. 
(C) Areas under the curve were calculated from tube length data in (B). Data are 
means±SEM for n=4. *p < 0.5.  
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Supplemental Figure 2. Reactome pathways corresponding to changes in gene 
expression during palmitate treatment.  
Pathways overrepresented in the list of differentially expressed genes in human 
microvascular endothelial cells treated with 0.5 mM palmitate plus vehicle (A), 0.5 mM 
palmitate plus 10 μM niacin (B), or 0.5 mM palmitate plus 10 nM vitamin D (C) 
compared to BSA control. Top level pathways are represented by central nodes, with 
nodes in the outer rings representing sub-pathways. Relationships between nodes are 
represented by arcs (edges). Significantly (p < 0.05) overrepresented (enriched) pathways 
and relationships are indicated by increasing yellow signal. Black boxes 
 highlight comparisons in significantly overrepresented top-level pathways and associated 
sub-pathways between treatment groups.  
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Supplemental Figure 3. Blood pressure and heart rate are unaffected by vitamin 
supplementation.  
Five week old male 129S6 mice were fed a western diet for 15 weeks, followed by right 
hind limb femoral artery ligation and excision surgery. Mice received once daily i.p 
injections for 14 days following surgery of either vehicle, niacin (NA) (50 mg/kg), 
vitamin D (Vit D) (200 ng/kg), or a combination of NA and Vit D (50 mg/kg and 200 
ng/kg, respectively). Three days before the surgery (Pre-surgery), and on day 14 
following surgery (Post-surgery), blood pressure and heart rate were measured using tail-
cuff plethysmography. (A) Mean systolic blood pressure pre- and post-surgery. Data are 
means±SEM for n=15 for pre-surgery and n=8 for post-surgery. (B) Mean systolic blood 
pressure (mmHg) and (C) mean heart rate (bpm). Data are means±SEM for n=15 for pre-
surgery and n=8 for post-surgery, n=3 for vehicle, n=2 for NA, n=2 for Vit D and n=1 for 
NA and Vit D. 
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